2024

McInnes, I. , Sewerin, P., Sharaf, M., Efficace, M., Lavie, F., Zimmermann, M. and Coates, L. C. (2024) Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial. RMD Open, 10(4), e004494. (doi: 10.1136/rmdopen-2024-004494) (PMID:39672591)

MacDonald, L. et al. (2024) Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis. Immunity, (doi: 10.1016/j.immuni.2024.11.004) (PMID:39609125) (Early Online Publication)

Colton, H. et al. (2024) Greater preservation of SARS‐CoV‐2 neutralising antibody responses following the ChAdOx1‐S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients. British Journal of Haematology, (doi: 10.1111/bjh.19874) (PMID:39551718) (Early Online Publication)

Mease, P. J. et al. (2024) Persistent patient‐level effect of guselkumab at consecutive 8‐week dosing visits and over time in patients with active psoriatic arthritis: post hoc analysis of a 2‐year, phase 3, randomized, controlled study. ACR Open Rheumatology, (doi: 10.1002/acr2.11732) (PMID:39365294) (Early Online Publication)

Mease, P. J. et al. (2024) Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies. Rheumatology and Therapy, 11, pp. 1363-1382. (doi: 10.1007/s40744-024-00708-8) (PMID:39215949)

Asghar, S., Litherland, G. J., Cole, J. J., McInnes, I. B. , Meek, R.M.D., Lockhart, J. C., Goodyear, C. S. and Crilly, A. (2024) Small extracellular vesicles derived from synovial fibroblasts contain distinct miRNA profiles and contribute to chondrocyte damage in osteoarthritis. Arthritis Research and Therapy, 26(1), 167. (doi: 10.1186/s13075-024-03398-3) (PMID:39342381)

Malamud, M. et al. (2024) Recognition and control of neutrophil extracellular trap formation by MICL. Nature, 633(8029), pp. 442-450. (doi: 10.1038/s41586-024-07820-3) (PMID:39143217)

Mease, P. J., Warren, R. B., Nash, P., Grouin, J.-M., Lyris, N., Taieb, V., Eells, J. and McInnes, I. B. (2024) Comparative effectiveness of bimekizumab and ustekinumab in patients with psoriatic arthritis at 52 weeks assessed using a matching-adjusted indirect comparison. Rheumatology and Therapy, 11(5), pp. 1413-1423. (doi: 10.1007/s40744-024-00705-x) (PMID:39120848)

Mease, P. J., Warren, R. B., Nash, P., Grouin, J.-M., Lyris, N., Willems, D., Taieb, V., Eells, J. and McInnes, I. B. (2024) Comparative effectiveness of bimekizumab and risankizumab in patients with psoriatic arthritis at 52 weeks assessed using a matching-adjusted indirect comparison. Rheumatology and Therapy, 11(5), pp. 1403-1412. (doi: 10.1007/s40744-024-00706-w) (PMID:39120849)

McInnes, I. B. et al. (2024) Efficacy and safety of bimekizumab in patients with psoriatic arthritis with or without methotrexate: 52-week results from two phase 3 studies. ACR Open Rheumatology, (doi: 10.1002/acr2.11727) (PMID:39077886) (Early Online Publication)

Ritchlin, C. T. et al. (2024) Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical Rheumatology, 43(8), pp. 2551-2563. (doi: 10.1007/s10067-024-06991-8) (PMID:38844682) (PMCID:PMC11269379)

Leston, M., Ordóñez-Mena, J., Joy, M., de Lusignan, S., Hobbs, R., McInnes, I. and Lee, L. (2024) Defining and risk-stratifying immunosuppression (the DESTINIES study): protocol for an electronic Delphi study. JMIR Research Protocols, 13, e56271. (doi: 10.2196/56271) (PMID:38842925) (PMCID:11190617)

Mease, P. J., Warren, R. B., Nash, P., Grouin, J.-M., Lyris, N., Willems, D., Taieb, V., Eells, J. and McInnes, I. B. (2024) Comparative effectiveness of bimekizumab and secukinumab in patients with psoriatic arthritis at 52 weeks using a matching-adjusted indirect comparison. Rheumatology and Therapy, 11, pp. 817-828. (doi: 10.1007/s40744-024-00652-7) (PMID:38446397) (PMCID:PMC11111635)

Gossec, L. et al. (2024) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Annals of the Rheumatic Diseases, 83(6), pp. 706-719. (doi: 10.1136/ard-2024-225531) (PMID:38499325) (PMCID:PMC11103320)

Kerschbaumer, A. et al. (2024) Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases, 83, pp. 760-774. (doi: 10.1136/ard-2024-225534) (PMID:38503473) (PMCID:PMC11103324)

Goodyear, C. S. et al. (2024) Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Rheumatology, 6(6), e339-e351. (doi: 10.1016/S2665-9913(24)00065-1) (PMID:38734019)

Rahman, P. et al. (2024) Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis. Clinical Rheumatology, 43(5), pp. 1591-1604. (doi: 10.1007/s10067-024-06921-8) (PMID:38472528) (PMCID:PMC11018666)

Tillett, W. R., Ink, B., Bajracharya, R., Taieb, V., Sharma, P., McGonagle, D., Coates, L. C. and McInnes, I. B. (2024) Sustained and consistent efficacy of bimekizumab in patients with active psoriatic arthritis regardless of prior TNF-inhibitor status: results from the phase 3 BE OPTIMAL and BE COMPLETE trials. British Society for Rheumatology Annual Conference 2024, Liverpool, UK, 24-26 April 2024. (doi: 10.1093/rheumatology/keae163.297)

Krueger, J. G. et al. (2024) IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Frontiers in Immunology, 15, 1331217. (doi: 10.3389/fimmu.2024.1331217) (PMID:38686385) (PMCID:PMC11056518)

Curtis, J. R. et al. (2024) Work productivity and general health through 2 years of guselkumab treatment in a phase 3 randomized trial of patients with active psoriatic arthritis. Rheumatology and Therapy, 11(2), pp. 425-441. (doi: 10.1007/s40744-024-00642-9) (PMID:38386178)

Shankar-Hari, M. et al. (2024) Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies. Lancet Respiratory Medicine, 12(4), pp. 323-336. (doi: 10.1016/S2213-2600(23)00468-X) (PMID:38408467) (PMCID:PMC11025021)

Warren, R. B., McInnes, I. B. , Nash, P., Grouin, J.-M., Lyris, N., Willems, D., Taieb, V., Eells, J. and Mease, P. J. (2024) Comparative effectiveness of bimekizumab and guselkumab in patients with psoriatic arthritis at 52 weeks assessed using a matching-adjusted indirect comparison. Rheumatology and Therapy, 11, pp. 829-839. (doi: 10.1007/s40744-024-00659-0) (PMID:38488975) (PMCID:PMC11111623)

Gravallese, E. M. and McInnes, I. B. (2024) Advances abound in immune mediated inflammatory diseases. Seminars in Arthritis and Rheumatism, 64S, 152318. (doi: 10.1016/j.semarthrit.2023.152318) (PMID:38042620)

Ferguson, L. D. , Molenberghs, G., Verbeke, G., Rahimi, K., Rao, S., McInnes, I. B. , McMurray, J. J.V. , Sattar, N. and Conrad, N. (2024) Gout and incidence of 12 cardiovascular diseases: a case–control study including 152 663 individuals with gout and 709 981 matched controls. Lancet Rheumatology, 6(3), e156-e167. (doi: 10.1016/S2665-9913(23)00338-7)

Coates, L. C. et al. (2024) Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open, 10(1), e003855. (doi: 10.1136/rmdopen-2023-003855) (PMID:38388171) (PMCID:PMC10884206)

McGonagle, D. et al. (2024) Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis. Rheumatology, (doi: 10.1093/rheumatology/keae060) (PMID:38341669) (Early Online Publication)

Coates, L. C., Rahman, P., Mease, P. J., Shawi, M., Rampakakis, E., Kollmeier, A. P., Xu, X. L., Chakravarty, S. D., McInnes, I. B. and Tam, L.-S. (2024) Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study. BMC Rheumatology, 8(1), 6. (doi: 10.1186/s41927-024-00375-w) (PMID:38310261) (PMCID:PMC10838435)

Charles-Schoeman, C. et al. (2024) Impact of upadacitinib on laboratory parameters and related adverse events in patients with RA: integrated data up to 6.5 years. Rheumatology and Therapy, 11(1), pp. 157-175. (doi: 10.1007/s40744-023-00624-3) (PMID:38180720) (PMCID:PMC10796877)

Camargo da Rosa, L. , Scales, H. E. , Benson, R. A. , Brewer, J. M. , McInnes, I. B. and Garside, P. (2024) The effect of abatacept on T cell activation is not long-lived in vivo. Discovery Immunology, 3(1), kyad029. (doi: 10.1093/discim/kyad029)

Paoletti, A. et al. (2024) Liposomal antagomiR-155-5p restores anti-inflammatory macrophages and improves arthritis in preclinical models of rheumatoid arthritis. Arthritis and Rheumatology, 76(1), pp. 18-31. (doi: 10.1002/art.42665) (PMID:37527031)

2023

Fragoulis, G. E., Ntouros, P. A., Nezos, A., Vlachogiannis, N. I., McInnes, I. B. , Tektonidou, M. G., Skarlis, C., Souliotis, V. L., Mavragani, C. P. and Sfikakis, P. P. (2023) Type-I interferon pathway and DNA damage accumulation in peripheral blood of patients with psoriatic arthritis. Frontiers in Immunology, 14, 1274060. (doi: 10.3389/fimmu.2023.1274060) (PMID:38124740) (PMCID:PMC10731026)

Brock, J., Basu, N. , Schlachetzki, J. C. M., Schett, G., McInnes, I. B. and Cavanagh, J. (2023) Immune mechanisms of depression in rheumatoid arthritis. Nature Reviews Rheumatology, 19(12), pp. 790-804. (doi: 10.1038/s41584-023-01037-w) (PMID:37923863)

Jaffery, H. et al. (2023) IĸB Protein BCL3 as a controller of osteogenesis and bone health. Arthritis and Rheumatology, 75(12), 2148-2160-2148-2160. (doi: 10.1002/art.42639) (PMID:37410754)

Porter, D., Jain, S., Qian, E., Morton, F. R. and McInnes, I. (2023) Time-varying risks of infection in patients as they proceed through the phases of ‘pre-RA’: results from the Scottish Early RA inception cohort. RMD Open, 9(4), e003224. (doi: 10.1136/rmdopen-2023-003224) (PMID:37996122)

Charles-Schoeman, C. et al. (2023) MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open, 9(4), e003392. (doi: 10.1136/rmdopen-2023-003392) (PMID:37945286) (PMCID:PMC10649869)

Ooms, A. et al. (2023) Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis. BMJ Open, 13(9), e078539. (doi: 10.1136/bmjopen-2023-078539) (PMID:37770264) (PMCID:PMC10546161)

Fragoulis, G. E., Vetsika, E.-K., Kyriakidi, M., Verrou, K.-M., Kollias, G., Tektonidou, M. G., McInnes, I. B. and Sfikakis, P. P. (2023) Distinct innate and adaptive immunity phenotypic profile at the circulating single-cell level in psoriatic arthritis. Clinical Immunology, 253, 109679. (doi: 10.1016/j.clim.2023.109679) (PMID:37336253)

O’Brien, C. M. et al. (2023) Number of days required to measure sedentary time and physical activity using accelerometery in rheumatoid arthritis: a reliability study. Rheumatology International, 43(8), pp. 1459-1465. (doi: 10.1007/s00296-023-05342-1) (PMID:37227468) (PMCID:PMC10261182)

Barnes, E. et al. (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine, 29(7), pp. 1760-1774. (doi: 10.1038/s41591-023-02414-4) (PMID:37414897) (PMCID:PMC10353927)

McInnes, I. B. and Merola, J. F. (2023) Questions about the BE OPTIMAL trial - authors' reply. Lancet, 401(10392), p. 1928. (doi: 10.1016/S0140-6736(23)00969-8) (PMID:37301582)

Merola, J. F. and McInnes, I. B. (2023) Questions about the BE COMPLETE trial - Authors' reply. Lancet, 401(10392), p. 1927. (doi: 10.1016/S0140-6736(23)00965-0) (PMID:37301581)

Conrad, N. et al. (2023) Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet, 401(10391), pp. 1878-1890. (doi: 10.1016/S0140-6736(23)00457-9) (PMID:37156255)

Rahman, P. et al. (2023) Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis. Journal of Rheumatology, 50(6), pp. 769-780. (doi: 10.3899/jrheum.220928) (PMID:36642439)

Aletaha, D. et al. (2023) Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the Rheumatic Diseases, 82(6), pp. 773-787. (doi: 10.1136/ard-2022-222784) (PMID:35953263)

Johnsson, H., Cole, J., McInnes, I. B. , Graham, G. and Siebert, S. (2023) Differences in transcriptional changes in psoriasis and psoriatic arthritis skin with immunoglobulin gene enrichment in psoriatic arthritis. Rheumatology, (doi: 10.1093/rheumatology/kead195) (PMID:37137278) (Early Online Publication)

Johnsson, H., Cole, J., Siebert, S. , McInnes, I. B. and Graham, G. (2023) Cutaneous lesions in psoriatic arthritis are enriched in chemokine transcriptomic pathways. Arthritis Research and Therapy, 25, 73. (doi: 10.1186/s13075-023-03034-6) (PMID:37131254) (PMCID:PMC10152590)

Winthrop, K. L. et al. (2023) Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022. Annals of the Rheumatic Diseases, 82(5), pp. 594-598. (doi: 10.1136/ard-2022-223528) (PMID:36702529)

Conrad, N., McInnes, I. B. , Mcmurray, J. J.V. and Sattar, N. (2023) Patients with a range of rheumatic diseases are at increased risk of cardiovascular disorders towards a re-evaluation of the European League against Rheumatism (EULAR)'s recommendations for cardiovascular risk management? Annals of the Rheumatic Diseases, 82(4), pp. 457-459. (doi: 10.1136/ard-2022-223315) (PMID:36442979)

McGonagle, D. et al. (2023) Guselkumab, a selective interleukin‐23 p19 subunit inhibitor, resolves dactylitis in patients with active psoriatic arthritis: pooled results through week 52 from two phase 3 studies. ACR Open Rheumatology, 5(4), pp. 227-240. (doi: 10.1002/acr2.11537) (PMID:36880890) (PMCID:PMC10100698)

Mease, P. J. et al. (2023) Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis. Rheumatology, 62(4), pp. 1417-1425. (doi: 10.1093/rheumatology/keac500) (PMID:36102818) (PMCID:PMC10070072)

Najm, A. , Goodyear, C. S. , McInnes, I. B. and Siebert, S. (2023) Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy. Nature Reviews Rheumatology, 19, pp. 153-165. (doi: 10.1038/s41584-022-00874-5) (PMID:36596924)

Malcolm, J. et al. (2023) C-terminal citrullinated peptide alters antigen-specific APC:T cell interactions leading to breach of immune tolerance. Journal of Autoimmunity, 135, 102994. (doi: 10.1016/j.jaut.2023.102994) (PMID:36706535)

McInnes, I. B. et al. (2023) Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study. Rheumatology and Therapy, 10(1), pp. 275-292. (doi: 10.1007/s40744-022-00499-w) (PMID:36243812) (PMCID:PMC9569172)

Coates, L. C. et al. (2023) Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. Rheumatology, 62(1), e1-e3. (doi: 10.1093/rheumatology/keac388) (PMID:35799375)

Gottlieb, A. B. et al. (2023) Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD Open, 9(1), e002789. (doi: 10.1136/rmdopen-2022-002789) (PMID:36828643) (PMCID:PMC9972414)

McInnes, I. B. et al. (2023) Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet, 401(10370), pp. 25-37. (doi: 10.1016/S0140-6736(22)02302-9) (PMID:36493791)

Merola, J. F. et al. (2023) Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet, 401(10370), pp. 38-48. (doi: 10.1016/S0140-6736(22)02303-0) (PMID:36495881)

Nyirenda, M. H., Nijjar, J. S., Frleta-Gilchrist, M., Gilchrist, D. S., Porter, D., Siebert, S. , Goodyear, C. S. and McInnes, I. B. (2023) JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation. RMD Open, 9(1), e002671. (doi: 10.1136/rmdopen-2022-002671) (PMID:36599629) (PMCID:PMC9815080)

Sattar, N. , McMurray, J. J. V. , McInnes, I. B. , Aroda, V. R. and Lean, M. E. J. (2023) Treating chronic diseases without tackling excess adiposity promotes multimorbidity. Lancet Diabetes and Endocrinology, 11(1), pp. 58-62. (doi: 10.1016/S2213-8587(22)00317-5) (PMID:36460014)

Smolen, J. S. et al. (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases, 82(1), pp. 3-18. (doi: 10.1136/ard-2022-223356) (PMID:36357155)

2022

Alivernini, S., Firestein, G. S. and McInnes, I. B. (2022) The pathogenesis of rheumatoid arthritis. Immunity, 55(12), pp. 2255-2270. (doi: 10.1016/j.immuni.2022.11.009) (PMID:36516818)

Coates, L. C. et al. (2022) Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis and Rheumatology, 74(12), pp. 1959-1970. (doi: 10.1002/art.42280) (PMID:35829656)

Landewé, R. B.M. et al. (2022) EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Annals of the Rheumatic Diseases, 81(12), pp. 1629-1639. (doi: 10.1136/annrheumdis-2021-222006) (PMID:35197264)

Bodmer, M., Itano, A. and McInnes, I. (2022) Harnessing the small intestinal axis to resolve systemic inflammation. Frontiers in Immunology, 13, 1060607. (doi: 10.3389/fimmu.2022.1060607) (PMID:36458009) (PMCID:PMC9706197)

Bain, K. A., Nichols, B., Kerbiriou, C., Moffat, F., Ijaz, U. Z. , Gerasimidis, K. , McInnes, I. B. , Åstrand, A., Holmes, S. and Milling, S. W. F. (2022) Stratification of alopecia areata reveals involvement of CD4 T cell populations and altered faecal microbiota. Clinical and Experimental Immunology, 210(2), pp. 175-186. (doi: 10.1093/cei/uxac088) (PMID:36200950) (PMCID:PMC9750826)

Curtis, J. R. et al. (2022) The effect of guselkumab on work productivity in biologic-naïve patients with active psoriatic arthritis through week 52 of the phase 3, randomized, placebo-controlled DISCOVER-2 trial. Advances in Therapy, 39(10), pp. 4613-4631. (doi: 10.1007/s12325-022-02270-7) (PMID:35947349)

Curtis, J. R. et al. (2022) The effect of guselkumab on general health state in biologic-naïve patients with active psoriatic arthritis through week 52 of the phase 3, randomized, placebo-controlled DISCOVER-2 trial. Advances in Therapy, 39(10), pp. 4632-4644. (doi: 10.1007/s12325-022-02269-0) (PMID:35947348)

Fragoulis, G. E., Nikiphorou, E., McInnes, I. B. and Siebert, S. (2022) Does age matter in psoriatic arthritis? A narrative review. Journal of Rheumatology, 49(10), pp. 1085-1091. (doi: 10.3899/jrheum.210349) (PMID:34393099)

Degboe, Y., Vastert, S. J., Prakken, B. J. and McInnes, I. B. (2022) How does age determine the development of human immune-mediated arthritis? Nature Reviews Rheumatology, 18(9), pp. 501-512. (doi: 10.1038/s41584-022-00814-3) (PMID:35948692) (PMCID:PMC9363867)

Bejad, M., Bonilha, C. S., McInnes, I. B. , Garside, P. and Benson, R. A. (2022) Tofacitinib inhibits CD4 T cell polarisation to Th1 during priming thereby leading to clinical impact in a model of experimental arthritis. Clinical and Experimental Rheumatology, 40(7), pp. 1313-1323. (doi: 10.55563/clinexprheumatol/4rqeg0) (PMID:34494958)

Colaço, K. et al. (2022) Association of cardiac biomarkers with cardiovascular outcomes in patients with psoriatic arthritis and psoriasis: a longitudinal cohort study. Arthritis and Rheumatology, 74(7), pp. 1184-1192. (doi: 10.1002/art.42079) (PMID:35261189)

Ovseiko, P. V. et al. (2022) Gender equity in academic rheumatology, current status and potential for improvement: a cross-sectional study to inform an EULAR task force. RMD Open, 8(2), e002518. (doi: 10.1136/rmdopen-2022-002518) (PMID:35940824) (PMCID:PMC9367178)

Stober, C. et al. (2022) Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) meeting. Journal of Rheumatology, 49(6 Sup1), pp. 57-63. (doi: 10.3899/jrheum.211336) (PMID:35365578)

Kastrati, K. et al. (2022) A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open, 8(2), e002359. (doi: 10.1136/rmdopen-2022-002359) (PMID:36260501) (PMCID:PMC9462104)

McInnes, I. B. , Iagnocco, A., Aletaha, D., Baraliakos, X., Bijlsma, J. W.J., Mateus, E. F., Szekanecz, Z., Vliet Vlieland, T. P.M. and Smolen, J. S. (2022) Reflections on a contemporary European tragedy. Annals of the Rheumatic Diseases, 81(6), pp. 747-748. (doi: 10.1136/annrheumdis-2022-222652) (PMID:35470159)

Merola, J. F., McInnes, I. B. , Deodhar, A. A., Dey, A. K., Adamstein, N. H., Quebe-Fehling, E., Aassi, M., Peine, M. and Mehta, N. N. (2022) Effect of secukinumab on traditional cardiovascular risk factors and inflammatory biomarkers: post hoc analyses of pooled data across three indications. Rheumatology and Therapy, 9(3), pp. 935-955. (doi: 10.1007/s40744-022-00434-z) (PMID:35305260) (PMCID:PMC9127026)

Reuter, K., Haupt, C., Molto, A., Cope, A., van Vollenhoven, R. F., Elewaut, D., Lories, R. and McInnes, I. B. (2022) Levelling the playing field of RMD research across Europe to address patients’ needs: the emerging EULAR Research Centre. RMD Open, 8(2), e002456. (doi: 10.1136/rmdopen-2022-002456) (PMID:35714997) (PMCID:PMC9207999)

Schett, G., Rahman, P., Ritchlin, C., McInnes, I. B. , Elewaut, D. and Scher, J. U. (2022) Psoriatic arthritis from a mechanistic perspective. Nature Reviews Rheumatology, 18(6), pp. 311-325. (doi: 10.1038/s41584-022-00776-6) (PMID:35513599)

Hendry, G. J. et al. (2022) Gait rehabilitation for foot and ankle impairments in early rheumatoid arthritis: a feasibility study of a new gait rehabilitation programme (GREAT Strides). Pilot and Feasibility Studies, 8, 115. (doi: 10.1186/s40814-022-01061-9) (PMID:35637495) (PMCID:PMC9150324)

Machado, P. M. et al. (2022) Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Annals of the Rheumatic Diseases, 81(5), pp. 695-709. (doi: 10.1136/annrheumdis-2021-221490) (PMID:34972811) (PMCID:PMC8720639)

McInnes, I. B. et al. (2022) A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology, 61(5), pp. 1783-1794. (doi: 10.1093/rheumatology/keab740) (PMID:34668515)

Gottlieb, A. B. et al. (2022) Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data. Acta Dermato Venereologica, 102, adv00698. (doi: 10.2340/actadv.v102.563) (PMID:35146532) (PMCID:PMC9631291)

Prendergast, C. T., Benson, R. A. , Scales, H. E. , Bonilha, C. S., Cole, J. J., McInnes, I. , Brewer, J. M. and Garside, P. (2022) Dissecting the molecular control of immune cell accumulation in the inflamed joint. JCI Insight, 7(7), e151281. (doi: 10.1172/jci.insight.151281) (PMID:35192549) (PMCID:PMC9057592)

Ritchlin, C. T. et al. (2022) Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open, 8(1), e002195. (doi: 10.1136/rmdopen-2022-002195) (PMID:35296534) (PMCID:PMC8928386)

Coates, L. C., Gossec, L., Theander, E., Bergmans, P., Neuhold, M., Karyekar, C. S., Shawi, M., Noël, W., Schett, G. and McInnes, I. B. (2022) Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Annals of the Rheumatic Diseases, 81(3), pp. 359-369. (doi: 10.1136/annrheumdis-2021-220991) (PMID:34819273)

Ferguson, L. D. et al. (2022) Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease – results of the Immune Metabolic Associations in Psoriatic Arthritis study. Rheumatology, 61(3), pp. 1026-1034. (doi: 10.1093/rheumatology/keab474) (PMID:34097014) (PMCID:PMC8889283)

McInnes, I. B. et al. (2022) Long‐term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin‐23, through 2 years: results from a phase 3, randomized, double‐blind, placebo‐controlled study conducted in biologic‐naïve patients with active psoriatic arthritis. Arthritis and Rheumatology, 74(3), pp. 475-485. (doi: 10.1002/art.42010) (PMID:34719872)

Mirza, M. et al. (2022) Impact of the COVID‐19 pandemic on recruitment to clinical research studies in rheumatology. Musculoskeletal Care, 20(1), pp. 209-213. (doi: 10.1002/msc.1561) (PMID:33938621) (PMCID:PMC8242596)

Alunno, A. et al. (2022) 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 81(1), pp. 34-40. (doi: 10.1136/annrheumdis-2021-221366) (PMID:34620584) (PMCID:PMC8507408)

Degboe, Y., Sunzini, F., Sood, S., Bozec, A., Sokolova, M. V., Zekovic, A., McInnes, I. B. , Schett, G. and Goodyear, C. S. (2022) Apremilast inhibits inflammatory osteoclastogenesis. Rheumatology, 61(1), pp. 452-461. (doi: 10.1093/rheumatology/keab315) (PMID:33788924)

Kolbinger, F. et al. (2022) Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacology and Therapeutics, 229, 107925. (doi: 10.1016/j.pharmthera.2021.107925) (PMID:34171337)

Krueger, J. G., McInnes, I. B. and Blauvelt, A. (2022) Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. Journal of the American Academy of Dermatology, 86(1), pp. 148-157. (doi: 10.1016/j.jaad.2021.06.869) (PMID:34224773)

McInnes, I. B. et al. (2022) Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD Open, 8(1), e002049. (doi: 10.1136/rmdopen-2021-002049) (PMID:35332058) (PMCID:PMC8948377)

McInnes, I. B. , Sawyer, L. M., Markus, K., LeReun, C., Sabry-Grant, C. and Helliwell, P. S. (2022) Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open, 8(1), e002074. (doi: 10.1136/rmdopen-2021-002074) (PMID:35321874) (PMCID:PMC8943739)

Nagy, G. et al. (2022) EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases, 81(1), pp. 20-33. (doi: 10.1136/annrheumdis-2021-220973) (PMID:34407926) (PMCID:PMC8761998)

Tanaka, Y., Kavanaugh, A., Wicklund, J. and McInnes, I. B. (2022) Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: an overview from clinical trials. Modern Rheumatology, 32(1), pp. 1-11. (doi: 10.1080/14397595.2021.1902617) (PMID:33740386)

Meehan, G. R. , Scales, H. E. , McInnes, I. B. , Brewer, J. M. and Garside, P. (2022) Orally administered antigen can reduce or exacerbate pathology in an animal model of inflammatory arthritis dependent upon the timing of administration. Immunotherapy Advances, 2(1), ltac020. (doi: 10.1093/immadv/ltac020) (PMID:36268500) (PMCID:PMC9579813)

2021

Gottlieb, A.B., Merola, J.F., Reich, K., Behrens, F., Nash, P., Griffiths, C.E.M., Bao, W., Pellet, P., Pricop, L. and McInnes, I.B. (2021) Efficacy of secukinumab and adalimumab in psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis: results from the EXCEED, a randomised, double‐blind head‐to‐head monotherapy study. British Journal of Dermatology, 185(6), pp. 1124-1134. (doi: 10.1111/bjd.20413) (PMID:33913511) (PMCID:PMC9291158)

McInnes, I. B. et al. (2021) Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open, 7(3), e001838. (doi: 10.1136/rmdopen-2021-001838) (PMID:34663636) (PMCID:PMC8524381)

McPeake, J. et al. (2021) Long-term outcomes following severe COVID-19 infection: a multicentre cohort study of family member outcomes. Annals of the American Thoracic Society, 18(12), pp. 2098-2101. (doi: 10.1513/AnnalsATS.202104-481RL) (PMID:34192506) (PMCID:PMC8641813)

Mease, P. J., Gladman, D. D., Kavanaugh, A., McGonagle, D., Nash, P., Guerette, B., Nakasato, P., Brunori, M., Teng, L. and McInnes, I. B. (2021) Articular and extra-articular benefits in ACR20 non-responders at week 104 treated with apremilast: pooled analysis of three randomized controlled trials. Rheumatology and Therapy, 8(4), pp. 1677-1691. (doi: 10.1007/s40744-021-00369-x) (PMID:34536218)

Rahman, P. et al. (2021) Pooled safety results through 1 year of 2 phase iii trials of guselkumab in patients with psoriatic arthritis. Journal of Rheumatology, 48(12), pp. 1815-1823. (doi: 10.3899/jrheum.201532) (PMID:33934076)

Akbar, M., MacDonald, L. , Crowe, L. A.N., Carlberg, K., Kurowska-Stolarska, M. , Ståhl, P. L., Snelling, S. J.B., McInnes, I. B. and Millar, N. L. (2021) Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis. Annals of the Rheumatic Diseases, 80(11), pp. 1494-1497. (doi: 10.1136/annrheumdis-2021-220256) (PMID:34001518) (PMCID:PMC8522454)

Colaco, K. et al. (2021) Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis. Annals of the Rheumatic Diseases, 80(11), pp. 1429-1435. (doi: 10.1136/annrheumdis-2021-220168) (PMID:34049856)

McGonagle, D. et al. (2021) Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. Rheumatology, 60(11), pp. 5337-5350. (doi: 10.1093/rheumatology/keab285) (PMID:33822898) (PMCID:PMC8566200)

Fragoulis, G. E., Brock, J., Basu, N. , McInnes, I. B. and Siebert, S. (2021) The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. Journal of Allergy and Clinical Immunology, 148(4), pp. 941-952. (doi: 10.1016/j.jaci.2021.08.010) (PMID:34450118)

Iagnocco, A., Aletaha, D., Baraliakos, X. and McInnes, I. B. (2021) Message from the new EULAR President and Steering Group. Annals of the Rheumatic Diseases, 80(10), pp. 1266-1267. (doi: 10.1136/annrheumdis-2021-221320) (PMID:34446430)

McInnes, I. B. and Gravallese, E. M. (2021) Immune-mediated inflammatory disease therapeutics: past, present and future. Nature Reviews Immunology, 21(10), pp. 680-686. (doi: 10.1038/s41577-021-00603-1) (PMID:34518662) (PMCID:PMC8436867)

Szekanecz, Z., McInnes, I. B. , Schett, G., Szamosi, S., Benkő, S. and Szűcs, G. (2021) Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nature Reviews Rheumatology, 17(10), pp. 585-595. (doi: 10.1038/s41584-021-00652-9) (PMID:34341562)

Akbar, M. et al. (2021) Translational targeting of inflammation and fibrosis in frozen shoulder: Molecular dissection of the T cell/IL-17A axis. Proceedings of the National Academy of Sciences of the United States of America, 118(39), e210271511. (doi: 10.1073/pnas.2102715118) (PMID:34544860) (PMCID:PMC8488623)

Schett, G., McInnes, I. B. and Neurath, M. F. (2021) Reframing immune-mediated inflammatory diseases through signature cytokine hubs. New England Journal of Medicine, 385(7), pp. 628-639. (doi: 10.1056/nejmra1909094) (PMID:34379924)

Garcia-Melchor, E., Cafaro, G., MacDonald, L. , Crowe, L. A.N., Sood, S., McLean, M., Fazzi, U., McInnes, I. B. , Akbar, M. and Millar, N. L. (2021) Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease. Annals of the Rheumatic Diseases, 80(8), pp. 1075-1085. (doi: 10.1136/annrheumdis-2020-219335) (PMID:33692018)

Pournara, E. et al. (2021) Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD Open, 7(3), e001845. (doi: 10.1136/rmdopen-2021-001845)

MacDonald, L. et al. (2021) COVID-19 and RA share SPP1 myeloid pathway that drives PD-L1pos neutrophils and CD14pos monocytes. JCI Insight, 6(13), e147413. (doi: 10.1172/jci.insight.147413) (PMID:34143756) (PMCID:PMC8328085)

Alunno, A. et al. (2021) EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 80(6), pp. 698-706. (doi: 10.1136/annrheumdis-2020-219724) (PMID:33547062) (PMCID:PMC7871226)

Ansalone, C. , Cole, J., Chilaka, S., Sunzini, F., Sood, S., Robertson, J., Siebert, S. , McInnes, I. B. and Goodyear, C. (2021) TNF is a homeostatic regulator of distinct epigenetically primed human osteoclast precursors. Annals of the Rheumatic Diseases, 80(6), pp. 748-757. (doi: 10.1136/annrheumdis-2020-219262) (PMID:33692019) (PMCID:PMC8142443)

Mease, P. J. et al. (2021) Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology, 60(5), pp. 2109-2121. (doi: 10.1093/rheumatology/keab119) (PMID:33844022) (PMCID:PMC8121447)

Pratt, A. G. et al. (2021) Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. Lancet Rheumatology, 3(5), e337-e346. (doi: 10.1016/S2665-9913(21)00061-8) (PMID:33928262) (PMCID:PMC8062952)

Sweet, K., Song, Q., Loza, M. J., McInnes, I. B. , Ma, K., Leander, K., Lakshminarayanan, V., Franks, C., Cooper, P. and Siebert, S. (2021) Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. RMD Open, 7(2), e001679. (doi: 10.1136/rmdopen-2021-001679) (PMID:34011674) (PMCID:PMC8137258)

McInnes, I. B. et al. (2021) Trial of upadacitinib and adalimumab for psoriatic arthritis. New England Journal of Medicine, 384(13), pp. 1227-1239. (doi: 10.1056/NEJMoa2022516) (PMID:33789011)

Ferguson, L. D. , Linge, J., Leinhard, O. D., Woodward, R., Hall Barrientos, P., Roditi, G., Radjenovic, A. , McInnes, I. B. , Siebert, S. and Sattar, N. (2021) Psoriatic arthritis is associated with adverse body composition predictive of greater coronary heart disease and type 2 diabetes propensity – a cross-sectional study. Rheumatology, 60(4), pp. 1858-1862. (doi: 10.1093/rheumatology/keaa604) (PMID:33147607)

McInnes, I. B. et al. (2021) Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through 1 year in biologic-naïve psoriatic arthritis patients. Arthritis and Rheumatology, 73(4), pp. 604-616. (doi: 10.1002/art.41553) (PMID:33043600)

Nijjar, J. S., Morton, F. R. , Bang, H., Buckley, C. D., van der Heijde, D., Gilmour, A., Paterson, C., McInnes, I. B. , Porter, D. and Raza, K. (2021) The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study. Lancet Rheumatology, 3(4), e284-e293. (doi: 10.1016/S2665-9913(20)30381-7) (PMID:34604794) (PMCID:PMC7611758)

Crowe, L. A.N., Melchor, E. G., Murrell, G. A.C., McInnes, I. B. , Akbar, M. and Millar, N. (2021) Stromal ‘activation’ markers do not confer pathogenic activity in tendinopathy. Translational Sports Medicine, 4(2), pp. 268-279. (doi: 10.1002/tsm2.204)

Ferguson, L. D. , Sattar, N. and McInnes, I. B. (2021) Managing cardiovascular risk in patients with rheumatic disease. Medical Clinics of North America, 105(2), pp. 247-262. (doi: 10.1016/j.mcna.2020.09.010) (PMID:33589100)

McInnes, I. (2021) Response to: 'Hydroxychloroquine shortages during the COVID-19 pandemic' by Mendel et al. Annals of the Rheumatic Diseases, 80, e32. (doi: 10.1136/annrheumdis-2020-217954) (PMID:32434826)

Atherton, C. M. et al. (2021) Vancomycin wrap for anterior cruciate ligament surgery. American Journal of Sports Medicine, 49(2), pp. 426-434. (doi: 10.1177/0363546520981570) (PMID:33406371) (PMCID:PMC7859666)

Mease, P. J., Helliwell, P. S., Hjuler, K. F., Raymond, K. and McInnes, I. (2021) Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Annals of the Rheumatic Diseases, 80(2), pp. 185-193. (doi: 10.1136/annrheumdis-2019-216835) (PMID:33106286) (PMCID:PMC7815636)

Millar, N. L. , Silbernagel, K. G., Thorborg, K., Kirwan, P. D., Galatz, L. M., Abrams, G. D., Murrell, G. A.C., McInnes, I. B. and Rodeo, S. A. (2021) Tendinopathy. Nature Reviews Disease Primers, 7, 1. (doi: 10.1038/s41572-020-00234-1) (PMID:33414454)

Nash, P. et al. (2021) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 80(1), pp. 71-87. (doi: 10.1136/annrheumdis-2020-218398) (PMID:33158881) (PMCID:PMC7788060)

Cole, M., Yap, C., Buckley, C., Ng, W. F., McInnes, I. , Filer, A., Siebert, S. , Pratt, A., Isaacs, J. D. and Stocken, D. D. (2021) TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis. Trials, 22(1), 433. (doi: 10.1186/s13063-021-05384-5) (PMID:34229728) (PMCID:PMC8259060)

Jones, S. A., Bryant, C., Lloyd, C. M., McInnes, I. and O’Neill, L. (2021) A vision for cytokine biology with 20/20 clarity. Function, 2(1), zqaa042. (doi: 10.1093/function/zqaa042) (PMID:35330968) (PMCID:PMC8788856)

McPeake, J. et al. (2021) Long-term outcomes following severe COVID-19 infection: a propensity matched cohort study. BMJ Open Respiratory Research, 8, e001080. (doi: 10.1136/bmjresp-2021-001080)

Najm, A. and McInnes, I. B. (2021) IL-23 orchestrating immune cell activation in arthritis. Rheumatology, 60(Suppl4), iv4-iv15. (doi: 10.1093/rheumatology/keab266) (PMID:34668017) (PMCID:PMC8527242)

Rayner, F. et al. (2021) BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study. BMC Rheumatology, 5, 22. (doi: 10.1186/s41927-021-00194-3) (PMID:34275488) (PMCID:PMC8286860)

2020

Fragoulis, G. E., Chatziodionysiou, K., Nikiphorou, E., Cope, A. and McInnes, I. B. (2020) Damage accrual in rheumatoid arthritis: evaluating the joint and beyond. Arthritis and Rheumatology, 72(12), pp. 1967-1970. (doi: 10.1002/art.41449) (PMID:32696608)

Kerschbaumer, A. et al. (2020) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open, 6(3), e001374. (doi: 10.1136/rmdopen-2020-001374) (PMID:33188136) (PMCID:PMC7856126)

Fragoulis, G. E., Cavanagh, J. , Tindell, A., Derakhshan, M., Paterson, C., Porter, D., McInnes, I. B. and Siebert, S. (2020) Depression and anxiety in an Early Rheumatoid Arthritis inception cohort. Associations with demographic, socioeconomic and disease features. RMD Open, 6, e001376. (doi: 10.1136/rmdopen-2020-001376) (PMID:33127857)

Guzik, T. J. et al. (2020) COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research, 116(10), pp. 1666-1687. (doi: 10.1093/cvr/cvaa106) (PMID:32352535) (PMCID:PMC7197627)

Alivernini, S. et al. (2020) Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nature Medicine, 26(8), pp. 1295-1306. (doi: 10.1038/s41591-020-0939-8) (PMID:32601335)

Mehta, P., Porter, J. C., Manson, J. J., Isaacs, J. D., Openshaw, P. J.M., McInnes, I. B. , Summers, C. and Chambers, R. C. (2020) Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. Lancet Respiratory Medicine, 8(8), pp. 822-830. (doi: 10.1016/S2213-2600(20)30267-8) (PMID:32559419)

Akbar, M., Garcia-Melchor, E., Chilaka, S., Little, K. J., Sood, S., Reilly, J. H., Liew, F. Y., McInnes, I. B. and Millar, N. L. (2020) Attenuation of Dupuytren’s fibrosis via targeting of the STAT-1 modulated IL-13RA1 response. Science Advances, 6(28), eaaz8272. (doi: 10.1126/sciadv.aaz8272) (PMID:32695877) (PMCID:PMC7351483)

Landewé, R. B.M. et al. (2020) EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the Rheumatic Diseases, 79(7), pp. 851-858. (doi: 10.1136/annrheumdis-2020-217877) (PMID:32503854)

MacRitchie, N., Frleta-Gilchrist, M., Sugiyama, A., Lawton, T., McInnes, I. B. and Maffia, P. (2020) Molecular Imaging of Inflammation - current and emerging technologies for diagnosis and treatment. Pharmacology and Therapeutics, 211, 107550. (doi: 10.1016/j.pharmthera.2020.107550)

McInnes, I. B. (2020) Finding the vulnerable checkpoint. Nature Reviews Immunology, 20(7), p. 409. (doi: 10.1038/s41577-020-0295-4) (PMID:32203326)

Mease, P. J., McInnes, I. B. , Strand, V., FitzGerald, O., Ahmad, H. A., Elbez, Y. and Banerjee, S. (2020) Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. Rheumatology International, 40, pp. 1021-1028. (doi: 10.1007/s00296-020-04564-x) (PMID:32356115) (PMCID:PMC7256096)

Sattar, N. , McInnes, I. B. and McMurray, J. J.V. (2020) Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation, 142(1), pp. 4-6. (doi: 10.1161/CIRCULATIONAHA.120.047659) (PMID:32320270)

Siebert, S. , McGucken, A. and McInnes, I. B. (2020) The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis? Current Opinion in Rheumatology, 32(4), pp. 349-356. (doi: 10.1097/BOR.0000000000000719) (PMID:32412997)

Vinci, .C. et al. (2020) Immunoglobulin A antibodies to oxidized collagen type II as a potential biomarker for the stratification of spondyloarthritis from rheumatoid arthritis. Scandinavian Journal of Rheumatology, 49(4), pp. 281-291. (doi: 10.1080/03009742.2020.1713395) (PMID:32314641)

Siebert, S. et al. (2020) Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: an early phase trial. Medicine, 99(26), e20458. (doi: 10.1097/MD.0000000000020458) (PMID:32590730) (PMCID:PMC7328978)

Daly, R. et al. (2020) Changes in plasma itaconate elevation in early rheumatoid arthritis patients elucidates disease activity associated macrophage activation. Metabolites, 10(6), 241. (doi: 10.3390/metabo10060241) (PMID:32531990) (PMCID:PMC7344783)

Gossec, L. et al. (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 79(6), pp. 700-712. (doi: 10.1136/annrheumdis-2020-217159) (PMID:32434812) (PMCID:PMC7286048)

Hsieh, P.-H., Wu, O. , Geue, C. , McIntosh, E. , McInnes, I. B. and Siebert, S. (2020) The economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Annals of the Rheumatic Diseases, 79(6), pp. 771-777. (doi: 10.1136/annrheumdis-2019-216243) (PMID:32245893)

Kerschbaumer, A. et al. (2020) Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 79(6), pp. 744-759. (doi: 10.1136/annrheumdis-2019-216656) (PMID:32033937) (PMCID:PMC7286044)

Kerschbaumer, A., Smolen, J. S., Dougados, M., de Wit, M., Primdahl, J., McInnes, I. , van der Heijde, D., Baraliakos, X., Falzon, L. and Gossec, L. (2020) Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases, 79(6), pp. 778-786. (doi: 10.1136/annrheumdis-2020-217163) (PMID:32381564)

Mease, P. J. et al. (2020) Treatment-to-target with apremilast in psoriatic arthritis: the probability of achieving targets and comprehensive control of disease manifestations. Arthritis Care and Research, 72(6), pp. 814-821. (doi: 10.1002/acr.24134) (PMID:31909868) (PMCID:PMC7317912)

Orbai, A.-M., McInnes, I. B. , Coates, L. C., Husni, M. E., Gladman, D. D., Gossec, L., Pricop, L., Chambenoit, O., Meng, X. and Mease, P. J. (2020) Effect of secukinumab on the different GRAPPA-OMERACT core domains in psoriatic arthritis: a pooled analysis of 2049 patients. Journal of Rheumatology, 47(6), pp. 854-864. (doi: 10.3899/jrheum.190507) (PMID:31615919)

Smolen, J. S. et al. (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 79(6), pp. 685-699. (doi: 10.1136/annrheumdis-2019-216655) (PMID:31969328)

McInnes, I. B. et al. (2020) Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet, 395(10235), pp. 1496-1505. (doi: 10.1016/S0140-6736(20)30564-X) (PMID:32386593)

McInnes, I. B. (2020) COVID-19 and rheumatology: first steps towards a different future? Annals of the Rheumatic Diseases, 79(5), pp. 551-552. (doi: 10.1136/annrheumdis-2020-217494) (PMID:32299844)

Gadina, M., Chisolm, D. A., Philips, R. L., McInnes, I. B. , Changelian, P. S. and O'Shea, J. J. (2020) Translating JAKs to Jakinibs. Journal of Immunology, 204(8), pp. 2011-2020. (doi: 10.4049/jimmunol.1901477) (PMID:32253269)

Pitaksalee, R. et al. (2020) Differential CpG DNA methylation in peripheral naïve CD4+ T-cells in early rheumatoid arthritis patients. Clinical Epigenetics, 12, 54. (doi: 10.1186/s13148-020-00837-1) (PMID:32264938) (PMCID:PMC7137446)

Deodhar, A., Gladman, D. D., McInnes, I. B. , Spindeldreher, S., Martin, R., Pricop, L., Porter, B., Safi Jr., J., Shete, A. and Bruin, G. (2020) Secukinumab immunogenicity over 52 weeks in patients with psoriatic arthritis and ankylosing spondylitis. Journal of Rheumatology, 47(4), pp. 539-547. (doi: 10.3899/jrheum.190116) (PMID:31203228)

Gracey, E., Burssens, A., Cambré, I., Schett, G., Lories, R., McInnes, I. B. , Asahara, H. and Elewaut, D. (2020) Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis. Nature Reviews Rheumatology, 16(4), pp. 193-207. (doi: 10.1038/s41584-019-0364-x) (PMID:32080619) (PMCID:PMC7815340)

Mease, P. J. et al. (2020) Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, 395(10230), pp. 1126-1136. (doi: 10.1016/S0140-6736(20)30263-4) (PMID:32178766)

Rodgers, L. C., Cole, J., Rattigan, K. M., Barrett, M. P. , Kurian, N., McInnes, I. B. and Goodyear, C. S. (2020) The rheumatoid synovial environment alters fatty acid metabolism in human monocytes and enhances CCL20 secretion. Rheumatology, 59(4), pp. 869-878. (doi: 10.1093/rheumatology/kez378) (PMID:31497857)

Cowan, G. J. M., Miles, K., Capitani, L., Giguere, S. S. B., Johnsson, H., Goodyear, C., McInnes, I. B. , Breusch, S., Gray, D. and Gray, M. (2020) In human autoimmunity, a substantial component of the B cell repertoire consists of polyclonal, barely mutated IgG +ve B cells. Frontiers in Immunology, 11, 395. (doi: 10.3389/fimmu.2020.00395) (PMID:32265907) (PMCID:PMC7099054)

Vieira-Sousa, E. et al. (2020) GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 79(4), pp. 490-498. (doi: 10.1136/annrheumdis-2019-216500) (PMID:32193187)

Kerrigan, S.A. and McInnes, I.B. (2020) Reflections on 'older' drugs: learning new lessons in rheumatology. Nature Reviews Rheumatology, 16(3), pp. 179-183. (doi: 10.1038/s41584-020-0375-7) (PMID:32066941)

Monnet, E., Choy, E. H., McInnes, I. , Kobakhidze, T., de Graaf, K., Jacqmin, P., Lapeyre, G. and de Min, C. (2020) Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study. Annals of the Rheumatic Diseases, 79, pp. 316-323. (doi: 10.1136/annrheumdis-2019-216487) (PMID:31892533)

Ritchlin, C. T. et al. (2020) Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet, 395(10222), pp. 427-440. (doi: 10.1016/S0140-6736(19)33161-7) (PMID:32035552)

Ogdie, A. et al. (2020) Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open, 6, e001042. (doi: 10.1136/rmdopen-2019-001042) (PMID:32396519) (PMCID:PMC6999680)

Garton, M., McInnes, I. B. and Sattar, N. (2020) Comment on: Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis. Rheumatology, 59(2), pp. 453-454. (doi: 10.1093/rheumatology/kez613) (PMID:31873738) (PMCID:31873738)

Bain, K.A. et al. (2020) Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease‐associated psychological morbidity. British Journal of Dermatology, 182(1), pp. 130-137. (doi: 10.1111/bjd.18008) (PMID:30980732)

Sunzini, F., McInnes, I. and Siebert, S. (2020) JAK inhibitors and infections risk: focus on herpes zoster. Therapeutic Advances in Musculoskeletal Disease, 12, 1759720X20936059. (doi: 10.1177/1759720X20936059) (PMID:32655703) (PMCID:PMC7328488)

2019

Coates, L. C. et al. (2019) Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies. Arthritis Research and Therapy, 21(1), 266. (doi: 10.1186/s13075-019-2055-z) (PMID:31801620) (PMCID:PMC6894120)

Ferguson, L. D. , Brown, R., Celis-Morales, C. , Welsh, P. , Lyall, D. M. , Pell, J. P. , McInnes, I. B. , Siebert, S. and Sattar, N. (2019) Association of central adiposity with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional study of the UK Biobank. Rheumatology, 58(12), pp. 2137-2142. (doi: 10.1093/rheumatology/kez192) (PMID:31131407) (PMCID:PMC6880847)

Lliso-Ribera, G. et al. (2019) Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). Annals of the Rheumatic Diseases, 78(12), pp. 1642-1652. (doi: 10.1136/annrheumdis-2019-215751) (PMID:31582377)

Finlay, S. et al. (2019) Presence of the MerTK Receptor on Human Synovial Tissue Macrophages Lowers Inflammatory Cytokine Production and Activation of the MerTK+CD206+ Subpopulation Limits the Inflammatory Response of Synovial Fibroblasts. 2019 ACR/ARP Annual Meeting, Atlanta, GA, USA, 08-13 Nov 2019.

Ferguson, L. , Welsh, P. , Brown, R., Tindell, A., Kerrigan, S., Sattar, N. , McInnes, I. and Siebert, S. (2019) Effect of Phosphodiesterase 4 Inhibition with Apremilast on Cardiometabolic Outcomes in Psoriatic Arthritis – Initial Results from the Immune Metabolic Associations in Psoriatic Arthritis (IMAPA) Study. In: 2019 ACR/ARP Annual Meeting, Atlanta, GA, 8-13 November 2019,

McInnes, I. B. , Puig, L., Gottlieb, A. B., Ritchlin, C., Song, M., You, Y., Kafka, S., Morgan, G. J., Rahman, P. and Kavanaugh, A. (2019) Association between enthesitis and health-related quality of life in psoriatic arthritis in anti-TNF-naïve patients from two Phase 3 ustekinumab trials. Journal of Rheumatology, 46(11), pp. 1458-1461. (doi: 10.3899/jrheum.180792) (PMID:30936281)

Cossarizza, A. et al. (2019) Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 49(10), pp. 1457-1973. (doi: 10.1002/eji.201970107) (PMID:31633216)

Gladman, D. D. et al. (2019) Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis acrossphase III and long‐term extension studies. Arthritis Care and Research, 71(10), pp. 1387-1395. (doi: 10.1002/acr.23930) (PMID:31112005) (PMCID:PMC6764856)

Siebert, S. , Sweet, K., Dasgupta, B., Campbell, K., McInnes, I. B. and Loza, M. J. (2019) Responsiveness of serum C‐reactive protein, interleukin‐17A, and interleukin‐17F levels to ustekinumab in psoriatic arthritis: lessons from two phase III, multicenter, double‐blind, placebo‐controlled trials. Arthritis and Rheumatology, 71(10), pp. 1660-1669. (doi: 10.1002/art.40921) (PMID:31070869)

Charles‐Schoeman, C., DeMasi, R., Valdez, H., Soma, K., Hwang, L.‐J., Boy, M. G., Biswas, P. and McInnes, I. B. (2019) Risk factors for major adverse cardiovascular events in phase III and long‐term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis and Rheumatology, 71(9), pp. 1450-1459. (doi: 10.1002/art.40911) (PMID:31385441) (PMCID:PMC6754249)

McGonagle, D. G., McInnes, I. B. , Kirkham, B. W., Sherlock, J. and Moots, R. (2019) The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Annals of the Rheumatic Diseases, 78(9), pp. 1167-1178. (doi: 10.1136/annrheumdis-2019-215356) (PMID:31278139) (PMCID:PMC6788885)

McInnes, I. B. et al. (2019) Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Research and Therapy, 21(1), 183. (doi: 10.1186/s13075-019-1964-1) (PMID:31375130) (PMCID:PMC6679539)

Glatt, S., Taylor, P. C., McInnes, I. B. , Schett, G., Landewé, R., Baeten, D., Ionescu, L., Strimenopoulou, F., Watling, M. I.L. and Shaw, S. (2019) Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study. Annals of the Rheumatic Diseases, 78(8), pp. 1033-1040. (doi: 10.1136/annrheumdis-2018-214943) (PMID:31177099) (PMCID:PMC6691864)

Lewis, M. J. et al. (2019) Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Reports, 28(9), 2455-2470.e5. (doi: 10.1016/j.celrep.2019.07.091) (PMID:31461658) (PMCID:PMC6718830)

McInnes, I. B. , Chakravarty, S. D., Apaolaza, I., Kafka, S., Hsia, E. C., You, Y. and Kavanaugh, A. (2019) Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. RMD Open, 5(2), e000990. (doi: 10.1136/rmdopen-2019-000990) (PMID:31565242) (PMCID:PMC6744084)

Siebert, S. , Millar, N. L. and McInnes, I. B. (2019) Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Annals of the Rheumatic Diseases, 78(8), pp. 1015-1018. (doi: 10.1136/annrheumdis-2018-213654) (PMID:30297330) (PMCID:PMC6691857)

Al-Laith, M. et al. (2019) Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials, 20(1), 429. (doi: 10.1186/s13063-019-3403-7) (PMID:31307535) (PMCID:PMC6633323)

Elmesmari, A. et al. (2019) Do Functional Interactions Between Macrophages and Synovial Fibroblasts Drive Synovial Pathology or Resolution of Inflammation? European League Against Rheumatism (EULAR) 2019 Congress, Madrid, Spain, 12-15 Jun 2019.

Finlay, S. et al. (2019) Single-cell Transcriptomic and Functional Analyses Reveal Novel Heterogeneity in Pathogenic Pathways Mediated by Human Synovial Tissue Macrophages. European League Against Rheumatism (EULAR) 2019 Congress, Madrid, Spain, 12-15 Jun 2019.

Humby, F. et al. (2019) Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 78(6), pp. 761-772. (doi: 10.1136/annrheumdis-2018-214539) (PMID:30878974) (PMCID:PMC6579551)

Deodhar, A. et al. (2019) Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Research and Therapy, 21(1), 111. (doi: 10.1186/s13075-019-1882-2) (PMID:31046809) (PMCID:PMC6498580)

Leijten, E. F., Radstake, T. R., McInnes, I. B. and Jacobs, J. W. (2019) Limits of traditional evidence-based medicine methodologies exemplified by the novel era in psoriatic arthritis drug development. Expert Review of Clinical Immunology, 15(5), pp. 441-444. (doi: 10.1080/1744666x.2019.1580144) (PMID:30729823)

Strand, V. et al. (2019) Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. Journal of Comparative Effectiveness Research, 8(7), pp. 497-510. (doi: 10.2217/cer-2018-0141) (PMID:30806520)

Akbar, M. et al. (2019) Fibroblast activation and inflammation in frozen shoulder. PLoS ONE, 14(4), e0215301. (doi: 10.1371/journal.pone.0215301) (PMID:31013287) (PMCID:PMC6478286)

McInnes, I. B. , Ferraccioli, G., D'Agostino, M.-A., Le Bars, M., Banerjee, S., Ahmad, H. A., Elbez, Y. and Mease, P. J. (2019) Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial. RMD Open, 5(1), e000934. (doi: 10.1136/rmdopen-2019-000934) (PMID:31245054) (PMCID:PMC6560664)

Schreiber, S., Colombel, J.-F., Feagan, B. G., Reich, K., Deodhar, A. A., McInnes, I. B. , Porter, B., Das Gupta, A., Pricop, L. and Fox, T. (2019) Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Annals of the Rheumatic Diseases, 78(4), pp. 473-479. (doi: 10.1136/annrheumdis-2018-214273) (PMID:30674475) (PMCID:PMC6530077)

Watson, D. S., Krutzinna, J., Bruce, I. N., Griffiths, C. E.M., McInnes, I. B. , Barnes, M. R. and Floridi, L. (2019) Clinical applications of machine learning algorithms: beyond the black box. British Medical Journal, 364, l886. (doi: 10.1136/bmj.l886) (PMID:30862612)

Millar, N. L. , Siebert, S. and McInnes, I. B. (2019) Europe rules on harm from fluoroquinolone antibiotics. Nature, 566(7744), p. 326. (doi: 10.1038/d41586-019-00619-7) (PMID:30783286)

Crowe, L. A.N. et al. (2019) S100A8 & S100A9: alarmin mediated inflammation in tendinopathy. Scientific Reports, 9, 1463. (doi: 10.1038/s41598-018-37684-3) (PMID:30728384) (PMCID:PMC6365574)

Fragoulis, G. E., McInnes, I. B. and Siebert, S. (2019) JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology, 58(Supple), i43-i54. (doi: 10.1093/rheumatology/key276) (PMID:30806709) (PMCID:PMC6390879)

Nerurkar, L., Siebert, S. , McInnes, I. B. and Cavanagh, J. (2019) Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry, 6(2), pp. 164-173. (doi: 10.1016/S2215-0366(18)30255-4) (PMID:30366684)

Veale, D. J. et al. (2019) The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology, 58(2), pp. 197-205. (doi: 10.1093/rheumatology/key070) (PMID:29618084) (PMCID:PMC6343466)

Budu-Aggrey, A. et al. (2019) Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. PLoS Medicine, 16(1), e1002739. (doi: 10.1371/journal.pmed.1002739) (PMID:30703100) (PMCID:PMC6354959)

McLean, M. et al. (2019) Tranexamic acid toxicity in human periarticular tissues. Bone and Joint Research, 8(1), pp. 11-18. (doi: 10.1302/2046-3758.81.BJR-2018-0181.R1) (PMID:30800295) (PMCID:PMC6359888)

Ferguson, L. D. , Siebert, S. , McInnes, I. B. and Sattar, N. (2019) Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nature Reviews Rheumatology, 15, pp. 461-474. (doi: 10.1038/s41584-019-0256-0) (PMID:31292564)

2018

Kerrigan, S.A. and McInnes, I.B. (2018) JAK inhibitors in rheumatology: implications for paediatric syndromes? Current Rheumatology Reports, 20(12), 83. (doi: 10.1007/s11926-018-0792-7) (PMID:30406861) (PMCID:PMC6223710)

McInnes, I. B. and Siebert, S. (2018) The extending scope of kinase inhibition in immune diseases. Lancet, 392(10162), pp. 2328-2331. (doi: 10.1016/S0140-6736(18)32600-X) (PMID:30360966)

Roodenrijs, N. M.T. et al. (2018) Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. Annals of the Rheumatic Diseases, 77(12), pp. 1705-1709. (doi: 10.1136/annrheumdis-2018-213687) (PMID:30194273)

Tanaka, Y. et al. (2018) Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis. Arthritis and Rheumatology, 70(12), pp. 1923-1932. (doi: 10.1002/art.40680) (PMID:30058112)

McInnes, I. B. , Nash, P., Ritchlin, C., Choy, E. H., Kanters, S., Thom, H., Gandhi, K., Pricop, L. and Jugl, S. M. (2018) Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. Journal of Comparative Effectiveness Research, 7(11), pp. 1107-1123. (doi: 10.2217/cer-2018-0075) (PMID:30230361)

Just, S. A. et al. (2018) Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. RMD Open, 4(2), e000799. (doi: 10.1136/rmdopen-2018-000799) (PMID:30488001) (PMCID:PMC6241983)

Tom, B. D.M., Symmons, D. and RA-MAP Consortium:, (2018) Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data. RMD Open, 4(2), e000721. (doi: 10.1136/rmdopen-2018-000721) (PMID:30487994) (PMCID:PMC6241979)

Alivernini, S. et al. (2018) Histological Features and Tissue-Macrophage Phenotype of Synovial Biopsies Identify RA Patients in Sustained Remission at Risk of Disease Flare after Treatment Tapering or Discontinuation. 2018 ACR/ARHP Annual Meeting, Chicago, IL, 19-24 Oct 2018. (Unpublished)

Clunie, G. et al. (2018) Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study. Rheumatology Advances in Practice, 2(2), rky042. (doi: 10.1093/rap/rky042) (PMID:31431979) (PMCID:PMC6649900)

Radstake, T. R.D.J., McInnes, I. B. and Bijlsma, J. W.J. (2018) World Arthritis Day 2018 - perspectives on rheumatic musculoskeletal diseases. European Journal of Immunology, 48(10), pp. 1604-1606. (doi: 10.1002/eji.201870125)

Helmers, S. B., Bruton, M., Loell, I., Ulfgren, A.-K., Gracie, A. J., McInnes, I. B. and Lundberg, I. E. (2018) Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment. Rheumatology, 57(12), pp. 2149-2157. (doi: 10.1093/rheumatology/key222) (PMID:30102381)

Alivernini, S., Tolusso, B., Ferraccioli, G., Gremese, E., Kurowska-Stolarska, M. and McInnes, I.B. (2018) Driving chronicity in rheumatoid arthritis: perpetuating role of myeloid cells. Clinical and Experimental Immunology, 193(1), pp. 13-23. (doi: 10.1111/cei.13098) (PMID:29315512) (PMCID:PMC6038003)

Fragoulis, G. E., Paterson, C., Gilmour, A., Derakhshan, M. H., McInnes, I. B. , Porter, D. and Siebert, S. (2018) Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome. RMD Open, 4(2), e000739. (doi: 10.1136/rmdopen-2018-000739) (PMID:30402267) (PMCID:PMC6203094)

Taylor, J. C. et al. (2018) Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. Pharmacogenomics Journal, 18(4), pp. 528-538. (doi: 10.1038/s41397-018-0025-5) (PMID:29795407)

Taylor, P. C. et al. (2018) Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Annals of the Rheumatic Diseases, 77(7), pp. 988-995. (doi: 10.1136/annrheumdis-2017-212461) (PMID:29463520) (PMCID:PMC6029633)

Elmesmari, A., Alivernini, S., Tolusso, B., Bui, L., Vaughan, D. , Federico, F., Gremese, E., McInnes, I. B. and Kurowska-Stolarska, M. (2018) Stolarska Synovial Tissue CD1c+ Dendritic Cells in Rheumatoid Arthritis Express High Levels of the Epigenetic Regulator of Inflammation, Microrna-155 and Inflammatory Cytokines. EULAR 2018: Annual European Congress of Rheumatology, Amsterdam, Netherlands, 13-16 June 2018. (Unpublished)

Finlay, S., Alivernini, S., Elmesmari, A., Tolusso, B., Ferraccioli, G., Gremese, E., Petricca, L., McInnes, I. B. , Kurowska-Stolarska, M. and Filer, A. (2018) Activation of Mertk+cd206+ Subpopulation of Human Synovial Tissue-Resident Macrophages Limits Inflammatory Response. EULAR 2018: Annual European Congress of Rheumatology, Amsterdam, Netherlands, 13-16 June 2018. (Unpublished)

McInnes, I. B. , Mease, P. J., Schett, G., Kirkham, B., Strand, V., Williams, N., Fox, T., Pricop, L., Jugl, S. M. and Gandhi, K. K. (2018) Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Research and Therapy, 20, 113. (doi: 10.1186/s13075-018-1610-3) (PMID:29880010) (PMCID:PMC5992664)

Nash, P., McInnes, I. B. , Mease, P. J., Thom, H., Hunger, M., Karabis, A., Gandhi, K., Mpofu, S. and Jugl, S. M. (2018) Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison. Rheumatology and Therapy, 5(1), pp. 99-122. (doi: 10.1007/s40744-018-0106-6) (PMID:29605841) (PMCID:PMC5935619)

Cooles, F. A.H., Anderson, A. E., Skelton, A., Pratt, A. G., Kurowska-Stolarska, M. S. , McInnes, I. , Hilkens, C. M.U. and Isaacs, J. D. (2018) Phenotypic and transcriptomic analysis of peripheral blood plasmacytoid and conventional dendritic cells in early drug naïve rheumatoid arthritis. Frontiers in Immunology, 9, 755. (doi: 10.3389/fimmu.2018.00755) (PMID:29867920) (PMCID:PMC5968398)

Bergmann, B., Jirholt, P., Henning, P., Lindholm, C., Ohlsson, C., McInnes, I. B. , Lerner, U. H. and Gjertsson, I. (2018) Antibiotics with Interleukin-15 inhibition reduces joint inflammation and bone erosions but not cartilage destruction in Staphylococcus aureus-induced arthritis. Infection and Immunity, 86(5), e00960-17. (doi: 10.1128/IAI.00960-17) (PMID:29440371)

Burmester, G. R. et al. (2018) Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor α monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis. Arthritis and Rheumatology, 70(5), pp. 679-689. (doi: 10.1002/art.40420) (PMID:29361199)

Elshabrawy, H. A. et al. (2018) IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells. Angiogenesis, 21(2), pp. 215-228. (doi: 10.1007/s10456-017-9589-y) (PMID:29327326)

Cafaro, G. and McInnes, I. B. (2018) Psoriatic arthritis: tissue-directed inflammation? Clinical Rheumatology, 37(4), pp. 859-868. (doi: 10.1007/s10067-018-4012-7) (PMID:29476352)

Prendergast, C. T., Patakas, A., Al-Khabouri, S., McIntyre, C. L., McInnes, I. B. , Brewer, J. M. , Garside, P. and Benson, R. A. (2018) Visualising the interaction of CD4 T cells and DCs in the evolution of inflammatory arthritis. Annals of the Rheumatic Diseases, 77(4), pp. 579-588. (doi: 10.1136/annrheumdis-2017-212279) (PMID:29358281)

Hecht, I. et al. (2018) ILDR2 is a novel B7-like protein that negatively regulates T cell responses. Journal of Immunology, 200(6), pp. 2025-2037. (doi: 10.4049/jimmunol.1700325) (PMID:29431694)

Nash, P. et al. (2018) Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Research and Therapy, 20(1), 47. (doi: 10.1186/s13075-018-1551-x) (PMID:29544534) (PMCID:PMC5856314)

Smolen, J. S. et al. (2018) Rheumatoid arthritis. Nature Reviews Disease Primers, 4, 18001. (doi: 10.1038/nrdp.2018.1) (PMID:29417936)

Carini, C., Hunter, E., Scottish Early Rheumatoid Arthritis Inception cohort, , Ramadass, A. S., Green, J., Akoulitchev, A., McInnes, I. B. and Goodyear, C. S. (2018) Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis. Journal of Translational Medicine, 16(1), 18. (doi: 10.1186/s12967-018-1387-9) (PMID:29378619) (PMCID:PMC5789697)

Alivernini, S., Gremese, E., McSharry, C., Tolusso, B., Ferraccioli, G., McInnes, I. B. and Kurowska-Stolarska, M. (2018) MicroRNA-155—at the critical interface of innate and adaptive immunity in arthritis. Frontiers in Immunology, 8, 1932. (doi: 10.3389/fimmu.2017.01932) (PMID:29354135) (PMCID:PMC5760508)

Benson, R. A. , McInnes, I. B. , Garside, P. and Brewer, J. M. (2018) Model answers: rational application of murine models in Arthritis research. European Journal of Immunology, 48(1), pp. 32-38. (doi: 10.1002/eji.201746938) (PMID:29193037) (PMCID:PMC5814907)

Smolen, J. S. et al. (2018) Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 77(1), pp. 3-17. (doi: 10.1136/annrheumdis-2017-211734) (PMID:28684559) (PMCID:PMC5754738)

Weinblatt, M. E. et al. (2018) A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis. Arthritis and Rheumatology, 70(1), pp. 49-59. (doi: 10.1002/art.40323) (PMID:28941039) (PMCID:PMC5767745)

Elmesmari, A., Alivernini, S., Tolusso, B., Vaughan, D. , Petricca, L., Gremese, E., Ferraccioli, G., McInnes, I. B. and Kurowska-Stolarska, M. (2018) Synovial Tissue of RA Patients in Remission Contains a Unique Population of Regulatory Macrophages. Microphage Biology in the Single-Cell Era, Ghent, Belgium, 2018. (Unpublished)

Noonan, J. et al. (2018) In vivo multiplex molecular imaging of vascular inflammation using surface-enhanced Raman spectroscopy. Theranostics, 8(22), pp. 6195-6209. (doi: 10.7150/thno.28665) (PMID:30613292) (PMCID:PMC6299693)

2017

Cope, A. P. et al. (2017) The RA-MAP Consortium: a working model for academia-industry collaboration. Nature Reviews Rheumatology, 14, pp. 53-60. (doi: 10.1038/nrrheum.2017.200) (PMID:29213124)

Pollock, J., Raza, K., Pratt, A. G., Hanson, H., Siebert, S. , Filer, A., Isaacs, J. D., Buckley, C. D., McInnes, I. B. and Falahee, M. (2017) Patient and researcher perspectives on facilitating patient and public involvement in rheumatology research. Musculoskeletal Care, 15(4), pp. 395-399. (doi: 10.1002/msc.1171) (PMID:27982541) (PMCID:PMC5808150)

Jaigrdar, S. A., Benson, R. A. , Elmesmari, A., Kurowska-Stolarska, M. S. , McInnes, I. B. , Garside, P. and Macleod, M. K.L. (2017) Sphingosine-1-phosphate promotes the persistence of activated CD4 T cells in inflamed sites. Frontiers in Immunology, 8, 1627. (doi: 10.3389/fimmu.2017.01627) (PMID:29225602) (PMCID:PMC5705559)

McInnes, I. B. , Mease, P. J., Ritchlin, C. T., Rahman, P., Gottlieb, A. B., Kirkham, B., Kajekar, R., Delicha, E.-M., Pricop, L. and Mpofu, S. (2017) Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology, 56(11), pp. 1993-2003. (doi: 10.1093/rheumatology/kex301) (PMID:28968735)

Watts, A. E. et al. (2017) MicroRNA29a treatment improves early tendon injury. Molecular Therapy, 25(10), pp. 2415-2426. (doi: 10.1016/j.ymthe.2017.07.015) (PMID:28822690)

Cossarizza, A. et al. (2017) Guidelines for the use of flow cytometry and cell sorting in immunological studies. European Journal of Immunology, 47(10), pp. 1584-1797. (doi: 10.1002/eji.201646632) (PMID:29023707)

Marton, N. et al. (2017) Extracellular vesicles regulate the human osteoclastogenesis: divergent roles in discrete inflammatory arthropathies. Cellular and Molecular Life Sciences, 74(19), pp. 3599-3611. (doi: 10.1007/s00018-017-2535-8) (PMID:28493076)

Robertson, J., Porter, D., Sattar, N. , Packard, C. J. , Caslake, M., McInnes, I. and McCarey, D. (2017) Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 76(11), pp. 1949-1952. (doi: 10.1136/annrheumdis-2017-211708) (PMID:28916714)

Baldwin, H. M., Singh, M. D., Codullo, V., King, V., Wilson, H., McInnes, I. and Graham, G. J. (2017) Elevated ACKR2 expression is a common feature of inflammatory arthropathies. Rheumatology, 56(9), pp. 1607-1617. (doi: 10.1093/rheumatology/kex176) (PMID:28486662) (PMCID:PMC5850605)

Orr, C. et al. (2017) Synovial tissue research: a state-of-the-art review. Nature Reviews Rheumatology, 13(8), pp. 463-475. (doi: 10.1038/nrrheum.2017.115) (PMID:28701760)

Akbar, M. et al. (2017) Targeting danger molecules in tendinopathy: the HMGB1/TLR4 axis. RMD Open, 3(2), e000456. (doi: 10.1136/rmdopen-2017-000456) (PMID:28879051) (PMCID:PMC5574425)

Burmester, G. R., Bijlsma, J. W.J., Cutolo, M. and McInnes, I. B. (2017) Managing rheumatic and musculoskeletal diseases - past, present and future. Nature Reviews Rheumatology, 13(7), pp. 443-448. (doi: 10.1038/nrrheum.2017.95) (PMID:28615732)

Kurow, O. et al. (2017) Full length interleukin 33 aggravates radiation-induced skin reaction. Frontiers in Immunology, 8, 722. (doi: 10.3389/fimmu.2017.00722) (PMID:28702024) (PMCID:PMC5487387)

Kurowska-Stolarska, M. et al. (2017) MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. Nature Communications, 8, 15877. (doi: 10.1038/ncomms15877) (PMID:28639625) (PMCID:PMC5489689)

Elmesmari, A., Alivernini, S., Tolusso, B., Vaughan, D. , Petricca, L., Gremese, E., Ferraccioli, G., McInnes, I. B. and Kurowska-Stolarska, M. (2017) Synovial Tissue of RA Patients in Remission Contains a Unique Population of Regulatory Macrophages. EULAR 2017: Annual European Congress of Rheumatology, Madrid, Spain, 14-17 June 2017. (Unpublished)

McInnes, I. B. and Schett, G. (2017) Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet, 389(10086), pp. 2328-2337. (doi: 10.1016/S0140-6736(17)31472-1) (PMID:28612747)

Jeffery, L., Fisk, H. L., Calder, P. C., Filer, A., Raza, K., Buckley, C. D., McInnes, I. , Taylor, P. C. and Fisher, B. A. (2017) Plasma levels of eicosapentaenoic acid are associated with anti-TNF responsiveness in rheumatoid arthritis and inhibit the etanercept-driven rise in Th17 cell differentiation in vitro. Journal of Rheumatology, 44(6), pp. 748-756. (doi: 10.3899/jrheum.161068) (PMID:28202745)

Smolen, J. S. et al. (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 76(6), pp. 960-977. (doi: 10.1136/annrheumdis-2016-210715) (PMID:28264816)

Burmester, G. R. et al. (2017) A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases, 76(6), pp. 1020-1030. (doi: 10.1136/annrheumdis-2016-210624) (PMID:28213566)

Cheung, T. T. and McInnes, I. B. (2017) Future therapeutic targets in rheumatoid arthritis? Seminars in Immunopathology, 39(4), pp. 487-500. (doi: 10.1007/s00281-017-0623-3) (PMID:28451787)

Kurowska-Stolarska, M. et al. (2017) The role of microRNA-155/LXR pathway in experimental and Idiopathic Pulmonary Fibrosis. Journal of Allergy and Clinical Immunology, 139(6), pp. 1946-1956. (doi: 10.1016/j.jaci.2016.09.021) (PMID:27746237) (PMCID:PMC5457127)

McInnes, I. B. , Porter, D. and Siebert, S. (2017) Editorial: choosing new targets for rheumatoid arthritis therapeutics: too interesting to fail? Arthritis and Rheumatology, 69(6), pp. 1131-1134. (doi: 10.1002/art.40082) (PMID:28245351)

Mease, P. J., Kavanaugh, A., Coates, L. C., McInnes, I. B. , Hojnik, M., Zhang, Y., Anderson, J. K., Dorr, A. P. and Gladman, D. D. (2017) Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. RMD Open, 3(1), e000415. (doi: 10.1136/rmdopen-2016-000415)

Elmesmari, A., Alivernini, S., Vaughan, D. , Ferraccioli, G., McInnes, I. B. and Kurowska-Stolarska, M. (2017) Characterisation of Synovium Tissues Macropahges. Rheumatology 2017, Birmingham, UK, 25-27 April 2017. (Unpublished)

Bayes, H. K., McInnes, I. B. and Chalmers, G. W. (2017) Castleman disease and lymphocytic interstitial pneumonia: a complex diagnostic and management challenge. Rheumatology, 56(4), pp. 665-668. (doi: 10.1093/rheumatology/kew420) (PMID:28013210)

Kim, S.-J. et al. (2017) Differential impact of obesity on the pathogenesis of RA or preclinical models is contingent on the disease status. Annals of the Rheumatic Diseases, 76(4), pp. 731-739. (doi: 10.1136/annrheumdis-2016-209206) (PMID:27797749)

Elmesmari, A., Alivernini, S., Tolusso, B., Vaughan, D. , Petricca, L., Gremese, E., Ferraccioli, G., McInnes, I. B. and Kurowska-Stolarska, M. (2017) Synovial Tissue of RA Patients in Remission Contains a Unique Population of Regulatory Macrophages. 37th European Workshop for Rheumatology Research (EWRR 2017), Athens, Greece, 2-4 March 2017. (Unpublished)

Tindell, A., Johnsson, H. and McInnes, I. B. (2017) Arthritis, arthropathy, and osteoporosis in inflammatory bowel disease. In: Baumgart, D. (ed.) Crohn's Disease and Ulcerative Colitis. Springer, pp. 571-583. ISBN 9783319337012 (doi: 10.1007/978-3-319-33703-6_55)

Firestein, G. S. and McInnes, I. B. (2017) Immunopathogenesis of rheumatoid arthritis. Immunity, 46(2), pp. 183-196. (doi: 10.1016/j.immuni.2017.02.006) (PMID:28228278) (PMCID:PMC5385708)

Millar, N. L. , Murrell, G. A.C. and McInnes, I. B. (2017) Inflammatory mechanisms in tendinopathy - towards translation. Nature Reviews Rheumatology, 13(2), pp. 110-122. (doi: 10.1038/nrrheum.2016.213) (PMID:28119539)

Siebert, S. , Porter, D., Paterson, C., Hampson, R., Gaya, D., Latosinska, A., Mischak, H., Schanstra, J., Mullen, W. and McInnes, I. (2017) Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. Scientific Reports, 7, 40473. (doi: 10.1038/srep40473) (PMID:28091549) (PMCID:PMC5320079)

Kalk, N.J. et al. (2017) Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [(11)C]PBR28 PET study. Translational Psychiatry, 7(1), e996. (doi: 10.1038/tp.2016.264) (PMID:28072413)

Millar, N. L. , O’Donnell, C., McInnes, I. B. and Brint, E. (2017) Wounds that heal and wounds that don’t − the role of the IL-33/ST2 pathway in tissue repair and tumorigenesis. Seminars in Cell and Developmental Biology, 61, pp. 41-50. (doi: 10.1016/j.semcdb.2016.08.007)

Agca, R. et al. (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the Rheumatic Diseases, 76, pp. 17-28. (doi: 10.1136/annrheumdis-2016-209775) (PMID:27697765)

2016

Claudepierre, P. et al. (2016) Association entre amélioration de l’enthésopathie et qualité de vie sous ustekinumab chez les patients atteints de rhumatisme psoriasique et naïfs d’anti-TNFs : données de 2 études de phase 3. 9e Congrès Français de Rhumatologie, Paris, France, 11-13 Dec 2016. (doi: 10.1016/S1169-8330(16)30456-2)

Mease, P. and McInnes, I. B. (2016) Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis. Rheumatology and Therapy, 3(2), p. 363. (doi: 10.1007/s40744-016-0039-x) (PMID:27747580) (PMCID:PMC5127963)

Rahman, P. et al. (2016) Ustekinumab treatment and improvement of physical function and health‐related quality of life in patients with psoriatic arthritis. Arthritis Care and Research, 68(12), pp. 1812-1822. (doi: 10.1002/acr.23000) (PMID:27483458) (PMCID:PMC5132036)

Dale, J. et al. (2016) The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 17, 461. (doi: 10.1186/s12891-016-1318-y) (PMID:27829394) (PMCID:PMC5103386)

Elmesmari, A., Fraser, A. R., Wood, C., Gilchrist, D., Vaughan, D. , Stewart, L., McSharry, C., McInnes, I. B. and Kurowska-Stolarska, M. (2016) MicroRNA-155 regulates monocyte chemokine and chemokine receptor expression in Rheumatoid Arthritis. Rheumatology, 55(11), pp. 2056-2065. (doi: 10.1093/rheumatology/kew272) (PMID:27411480) (PMCID:PMC5088623)

Fisher, B. A., Donatien, P., Filer, A., Winlove, C. P., McInnes, I. B. , Buckley, C. D. and Taylor, P. C. (2016) Decrease in articular hypoxia and synovial blood flow at early time points following infliximab and etanercept treatment in rheumatoid arthritis. Clinical and Experimental Rheumatology, 34(6), pp. 1072-1076. (PMID:27749236)

Huesa, C. et al. (2016) Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathology. Annals of the Rheumatic Diseases, 75(11), pp. 1989-1997. (doi: 10.1136/annrheumdis-2015-208268) (PMID:26698846) (PMCID:PMC5099200)

Kavanaugh, A., Puig, L., Gottlieb, A. B., Ritchlin, C., You, Y., Li, S., Song, M., Randazzo, B., Rahman, P. and McInnes, I. B. (2016) Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Annals of the Rheumatic Diseases, 75(11), pp. 1984-1988. (doi: 10.1136/annrheumdis-2015-209068) (PMID:27098404)

Welsh, P. , Tuckwell, K., McInnes, I. B. and Sattar, N. (2016) Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. Atherosclerosis, 254, pp. 167-171. (doi: 10.1016/j.atherosclerosis.2016.10.016) (PMID:27744141) (PMCID:PMC5110649)

Smolen, J. S., Aletaha, D. and McInnes, I. B. (2016) Rheumatoid arthritis. Lancet, 388(10055), pp. 2023-2038. (doi: 10.1016/S0140-6736(16)30173-8) (PMID:27156434)

Hatterer, E. et al. (2016) A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease. Arthritis Research and Therapy, 18(1), 224. (doi: 10.1186/s13075-016-1128-5) (PMID:27716430) (PMCID:PMC5053084)

Gabay, C., McInnes, I. B. , Kavanaugh, A., Tuckwell, K., Klearman, M., Pulley, J. and Sattar, N. (2016) Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 75(10), pp. 1806-1812. (doi: 10.1136/annrheumdis-2015-207872) (PMID:26613768) (PMCID:PMC5036214)

Alivernini, S. et al. (2016) MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. Nature Communications, 7, 12970. (doi: 10.1038/ncomms12970) (PMID:27671860) (PMCID:PMC5052655)

Fragoulis, G. E., Fragkioudaki, S., Reilly, J. H., Kerr, S. C., McInnes, I. B. and Moutsopoulos, H. B. (2016) Analysis of the cell populations composing the mononuclear cell infiltrates in the labial minor salivary glands from patients with rheumatoid arthritis and sicca syndrome. Journal of Autoimmunity, 73, pp. 85-91. (doi: 10.1016/j.jaut.2016.06.008) (PMID:27344240)

Kavanaugh, A., McInnes, I. B. , Mease, P. J., Hall, S., Chinoy, H., Kivitz, A. J., Wang, Z. and Mpofu, S. (2016) Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis atratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. Journal of Rheumatology, 43(9), pp. 1713-1717. (doi: 10.3899/jrheum.160275) (PMID:27307536)

McInnes, I. B. (2016) Psoriatic arthritis: embracing pathogenetic and clinical heterogeneity? Clinical and Experimental Rheumatology, 34(4 S98), pp. 9-11. (PMID:27586796)

van der Heijde, D., Landewé, R. B., Mease, P. J., McInnes, I. B. , Conaghan, P. G., Pricop, L., Ligozio, G., Richards, H. B. and Mpofu, S. (2016) Brief report: secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis. Arthritis and Rheumatology, 68(8), pp. 1914-1921. (doi: 10.1002/art.39685) (PMID:27014997)

Kronisch, C. et al. (2016) Brief report: predicting functional disability: one-year results from the Scottish Early Rheumatoid Arthritis inception cohort. Arthritis and Rheumatology, 68(7), pp. 1596-1602. (doi: 10.1002/art.39627) (PMID:26866516)

Li, R. et al. (2016) High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial. Medicine, 95(28), e3968. (doi: 10.1097/MD.0000000000003968) (PMID:27428186) (PMCID:PMC4956780)

Porter, D. et al. (2016) Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet, 388(10041), pp. 239-247. (doi: 10.1016/S0140-6736(16)00380-9) (PMID:27197690)

Redelinghuys, P. et al. (2016) MICL controls inflammation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 75(7), pp. 1386-1391. (doi: 10.1136/annrheumdis-2014-206644) (PMID:26275430) (PMCID:PMC4941174)

Millar, N. L. et al. (2016) IL-17A mediates inflammatory and tissue remodelling events in early human tendinopathy. Scientific Reports, 6, 27149. (doi: 10.1038/srep27149) (PMID:27263531) (PMCID:PMC4893609)

Ahmed, A., Hollan, I., Curran, S. A., Kitson, S. M., Riggio, M. P. , Mikkelsen, K., Almdahl, S. M., Aukrust, P., McInnes, I. B. and Goodyear, C. S. (2016) Rheumatoid arthritis patients have a pro-atherogenic cytokine microenvironment in the aortic adventitia. Arthritis and Rheumatology, 68(6), pp. 1361-1366. (doi: 10.1002/art.39574) (PMID:26749303) (PMCID:PMC4920270)

Malcolm, J. et al. (2016) Mast cells contribute to Porphyromonas gingivalis–induced bone loss. Journal of Dental Research, 95(6), pp. 704-710. (doi: 10.1177/0022034516634630) (PMID:26933137)

Gossec, L. et al. (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 75(3), pp. 499-510. (doi: 10.1136/annrheumdis-2015-208337)

Liu, Y. et al. (2016) A cytomegalovirus peptide-specific antibody alters natural killer cell homeostasis and ss shared in several autoimmune diseases. Cell Host and Microbe, 19(3), pp. 400-408. (doi: 10.1016/j.chom.2016.02.005) (PMID:26962948)

Patakas, A., Ji, R., Weir, W. , Connolly, S. E., Benson, R. A. , Nadler, S. G., Brewer, J. M. , McInnes, I. B. and Garside, P. (2016) Abatacept inhibits T cell priming by inducing of a unique transcriptional profile that reduces their ability to activate antigen presenting cells. Arthritis and Rheumatology, 68(3), pp. 627-638. (doi: 10.1002/art.39470) (PMID:26473409)

Sattar, N. and McInnes, I. (2016) Editorial: Lipid changes with different antiinflammatory regimens in rheumatoid arthritis: developing a pragmatic approach to complex data. Arthritis and Rheumatology, 68(3), pp. 563-565. (doi: 10.1002/art.39510) (PMID:26913842)

Baraliakos, X. et al. (2016) Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Annals of the Rheumatic Diseases, 75(2), pp. 408-412. (doi: 10.1136/annrheumdis-2015-207544) (PMID:26248638)

Kavanaugh, A., van der Heijde, D., Beutler, A., Gladman, D., Mease, P., Krueger, G. G., McInnes, I. B. , Helliwell, P., Coates, L. C. and Xu, S. (2016) Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study. Arthritis Care and Research, 68(2), pp. 267-274. (doi: 10.1002/acr.22576) (PMID:25779603)

Wright, P. B., McEntegart, A., McCarey, D., McInnes, I. B. , Siebert, S. and Milling, S. W. F. (2016) Ankylosing Spondylitis patients display altered dendritic cell and T cell populations that implicate pathogenic roles for the IL-23 cytokine axis and intestinal inflammation. Rheumatology, 55(1), pp. 120-132. (doi: 10.1093/rheumatology/kev245) (PMID:26320138) (PMCID:PMC4676904)

Fragoulis, G. E., Siebert, S. and McInnes, I. B. (2016) Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annual Review of Medicine, 67(1), pp. 337-353. (doi: 10.1146/annurev-med-051914-021944) (PMID:26565676)

Krishnadas, R. et al. (2016) Circulating Tumour Necrosis Factor is highly correlated with brainstem serotonin transporter availability in humans. Brain, Behavior, and Immunity, 51, pp. 29-38. (doi: 10.1016/j.bbi.2015.08.005) (PMID:26255693)

McInnes, I. , Buckley, C. D. and Isaacs, J. D. (2016) Cytokines in rheumatoid arthritis — shaping the immunological landscape. Nature Reviews Rheumatology, 12(1), pp. 63-68. (doi: 10.1038/nrrheum.2015.171) (PMID:26656659)

Mease, P. and McInnes, I. B. (2016) Secukinumab: a new treatment option for psoriatic arthritis. Rheumatology and Therapy, 3(1), pp. 5-29. (doi: 10.1007/s40744-016-0031-5) (PMID:27747518) (PMCID:PMC4999581)

Zarpelon, A. C. et al. (2016) Spinal cord oligodendrocyte-derived alarmin IL-33 mediates neuropathic pain. FASEB Journal, 30(1), pp. 54-65. (doi: 10.1096/fj.14-267146) (PMID:26310268)

Dale, J. et al. (2016) Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Annals of the Rheumatic Diseases, 75(6), pp. 1043-1050. (doi: 10.1136/annrheumdis-2015-208941) (PMID:27026689)

Elmesmari, A., Alivernini, S., McInnes, I. B. and Kurowska-Stolarska, M. (2016) Targeting miR-155 in Rheumatoid Arthritis B Cells Reduces Antibody Production. Scottish Society of Rheumatology Meeting 2016, Dundee, 2016. (Unpublished)

Kremer, J. M., Lawrence, D. A., Hamilton, R. and McInnes, I. B. (2016) Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. RMD Open, 2016(2), e000287. (doi: 10.1136/rmdopen-2016-000287) (PMID:27335660) (PMCID:PMC4913203)

Siebert, S. , Lyall, D. M. , Mackay, D. F. , Porter, D. and McInnes, I. B. (2016) Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502 649 UK Biobank participants. RMD Open, 2(1), e000267. (doi: 10.1136/rmdopen-2016-000267) (PMID:27403335) (PMCID:PMC4932291)

2015

Kavanaugh, A. et al. (2015) Maintenance of clinical efficacy and radiographic benefit through two years of Ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial. Arthritis Care and Research, 67(12), pp. 1739-1749. (doi: 10.1002/acr.22645) (PMID:26097039)

Johnsson, H.J. and McInnes, I.B. (2015) Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis. Clinical and Experimental Rheumatology, 5(Sup 93), S115-S118. (PMID:26471946)

Mease, P. J. et al. (2015) Secukinumab Inhibition of Interleukin-17A in patients with psoriatic arthritis. New England Journal of Medicine, 373(14), pp. 1329-1339. (doi: 10.1056/NEJMoa1412679) (PMID:26422723)

McInnes, I. B. et al. (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 386(9999), pp. 1137-1146. (doi: 10.1016/s0140-6736(15)61134-5) (PMID:26135703)

Jackson, C. E. et al. (2015) Combined free light chains are novel predictors of prognosis in heart failure. JACC: Heart Failure, 3(8), pp. 618-625. (doi: 10.1016/j.jchf.2015.03.014) (PMID:26251088)

Sattar, N. and McInnes, I. B. (2015) Rheumatoid arthritis: debunking the obesity–mortality paradox in RA. Nature Reviews Rheumatology, 11(8), pp. 445-446. (doi: 10.1038/nrrheum.2015.93) (PMID:26150124)

Hu, D. et al. (2015) Artery tertiary lymphoid organs control aorta immunity and protect against atherosclerosis via vascular smooth muscle cell lymphotoxin β receptors. Immunity, 42(6), pp. 1100-1115. (doi: 10.1016/j.immuni.2015.05.015) (PMID:26084025) (PMCID:PMC4678289)

Benson, R. A. , McInnes, I. B. , Brewer, J. M. and Garside, P. (2015) Cellular imaging in rheumatic diseases. Nature Reviews Rheumatology, 11(6), pp. 357-367. (doi: 10.1038/nrrheum.2015.34) (PMID:25800215)

Millar, N. L. , Gilchrist, D., Akbar, M., Reilly, J. H., Kerr, S. C., Campbell, A. L., Murrell, G. A.C., Liew, F. Y., Kurowska-Stolarska, M. and McInnes, I. B. (2015) MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease. Nature Communications, 6, 6774. (doi: 10.1038/ncomms7774) (PMID:25857925) (PMCID:PMC4403384)

McInnes, I. B. et al. (2015) Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Annals of the Rheumatic Diseases, 74(4), pp. 694-702. (doi: 10.1136/annrheumdis-2013-204345) (PMID:24368514) (PMCID:PMC4392313)

Oliver-Bell, J., Butcher, J.P., Malcolm, J. , Macleod, M.K.L. , Adrados Planell, A., Campbell, L., Nibbs, R.J.B. , Garside, P. , McInnes, I.B. and Culshaw, S. (2015) Periodontitis in the absence of B cells and specific anti-bacterial antibody. Oral Microbiology and Immunology, 30(2), pp. 160-169. (doi: 10.1111/omi.12082) (PMID:25219939)

Siebert, S. , Tsoukas, A., Robertson, J. and McInnes, I. (2015) Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacological Reviews, 67(2), pp. 280-309. (doi: 10.1124/pr.114.009639) (PMID:25697599)

Charles-Schoeman, C. et al. (2015) Potential mechanisms leading to the abnormal lipid profile in patients With rheumatoid arthritis versus healthy volunteers and reversal by Tofacitinib. Arthritis and Rheumatology, 67(3), pp. 616-625. (doi: 10.1002/art.38974) (PMID:25470338)

Kelly, S. et al. (2015) Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients. Annals of the Rheumatic Diseases, 74(3), pp. 611-617. (doi: 10.1136/annrheumdis-2013-204603) (PMID:24336336)

Hansell, C. A., MacLellan, L. M., Oldham, R. S., Doonan, J., Chapple, K. J., Anderson, E. J., Linington, C. , McInnes, I. B. , Nibbs, R. J. and Goodyear, C. S. (2015) The atypical chemokine receptor ACKR2 suppresses Th17 responses to protein autoantigens. Immunology and Cell Biology, 93(2), pp. 167-176. (doi: 10.1038/icb.2014.90) (PMID:25348934) (PMCID:PMC4340511)

Kristensen, S. L., McInnes, I. and Sattar, N. (2015) Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation? Annals of the Rheumatic Diseases, 74(2), pp. 321-322. (doi: 10.1136/annrheumdis-2014-206617) (PMID:25429028)

Nanus, D.E., Filer, A.D., Hughes, B., Fisher, B.A., Taylor, P.C., Stewart, P.M., Buckley, C.D., McInnes, I. , Cooper, M.S. and Raza, K. (2015) TNF regulates cortisol metabolism in vivo in patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 74(2), pp. 464-469. (doi: 10.1136/annrheumdis-2013-203926) (PMID:24385202)

Moraitis, A. G. et al. (2015) Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency. Journal of Clinical Lipidology, 9(1), pp. 81-90. (doi: 10.1016/j.jacl.2014.09.014) (PMID:25670364)

O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B. and Laurence, A. (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annual Review of Medicine, 66(1), pp. 311-328. (doi: 10.1146/annurev-med-051113-024537) (PMID:25587654)

Platt, A. M., Benson, R. A. , McQueenie, R., Butcher, J. P., Braddock, M., Brewer, J. M. , McInnes, I. B. and Garside, P. (2015) The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4+ T cell-priming capacity of dendritic cells. Rheumatology, 54(1), pp. 169-177. (doi: 10.1093/rheumatology/keu273) (PMID:25065010)

Tsoukas, A., Goodyear, C. S. and McInnes, I. B. (2015) Targeting the IL-17/IL-23 axis in chronic inflammatory immune-mediated diseases. In: Alt, F. W., Honjo, T., Radbruch, A. and Reth, M. (eds.) Molecular Biology of B Cells. Elsevier, pp. 527-539. ISBN 9780123979339 (doi: 10.1016/B978-0-12-397933-9.00028-X)

2014

Robertson, J., McInnes, I. and Sattar, N. (2014) Response to ‘Interleukin-6 signal transduction and its role in hepatic lipid metabolic disorders’ by Hassan et al. Cytokine, 70(2), p. 198. (doi: 10.1016/j.cyto.2014.05.028)

Elmesmari, A., Gilchrist, D. S., Fraser, A. R., Graham, G. J. , Brewer, J. , Kurowska-Stolarska, M. and McInnes, I. B. (2014) Mir-155 Expression Correlates with Clinical Disease Activity and has Effector Function in Rheumatoid Arthritis. 2014 ACR/ARHP Annual Meeting, Boston, MA, 14-19 Nov 2014. (Unpublished)

McInnes, I. B. and Siebert, S. (2014) Psoriatic arthritis - expanding options, exciting times? Acta Reumatologica Portuguesa, 39(4), pp. 294-295.

Kavanaugh, A. et al. (2014) Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Annals of the Rheumatic Diseases, 73(9), pp. 1689-1694. (doi: 10.1136/annrheumdis-2013-204902) (PMID:24748630)

Meier, F. M.P. and McInnes, I. B. (2014) Small-molecule therapeutics in rheumatoid arthritis: Scientific rationale, efficacy and safety. Best Practice and Research: Clinical Rheumatology, 28(4), pp. 605-624. (doi: 10.1016/j.berh.2014.10.017)

Elmesmari, A., Gilchrist, D. S., Fraser, A. R., Vaughan, D. , Graham, G. J. , Brewer, J. , Kurowska-Stolarska, M. and McInnes, I. B. (2014) MicroRNA-155 Regulates Chemokines and Chemokine Receptors in Rheumatoid Arthritis Monocytes. Libya Higher Education Forum, London, UK, 5-6 June 2014. (Unpublished)

Elmesmari, A., Pushparaj, P. N., Reilly, J., Kerr, S., Kurowska-Stolarska, M. and McInnes, I. B. (2014) Role of SPHKs and S1PRs in Rheumatoid Arthritis. 3rd European Congress of Immunology (ECI 2012), Glasgow, UK, 5-8 Sept 2012. (Unpublished)

McInnes, I. (2014) Fight against rheumatoid arthritis may unlock secrets to heart disease and depression. Australian Journal of Pharmacy, 95(1129), p. 12.

Nurmohamed, M. T., Jamnitski, A., Symmons, D., Peters, M. J. L., Sattar, N. and McInnes, I. (2014) Response to: 'The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritis' by Gonzalez-Gay et al. Annals of the Rheumatic Diseases, 73(5), e28. (doi: 10.1136/annrheumdis-2014-205174)

Rice, G. I. et al. (2014) Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nature Genetics, 46(5), pp. 503-509. (doi: 10.1038/ng.2933) (PMID:24686847) (PMCID:PMC4004585)

Patterson, H., Nibbs, R. , McInnes, I. and Siebert, S. (2014) Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clinical and Experimental Immunology, 176(1), pp. 1-10. (doi: 10.1111/cei.12248)

Dale, J., Purves, D., McConnachie, A. , McInnes, I. and Porter, D. (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care and Research, 66(1), pp. 19-26. (doi: 10.1002/acr.22218)

Dougados, M. et al. (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Annals of the Rheumatic Diseases, 73(1), pp. 62-68. (doi: 10.1136/annrheumdis-2013-204223)

Frleta, M., Siebert, S. and McInnes, I. B. (2014) The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment. Current Rheumatology Reports, 16(414), (doi: 10.1007/s11926-014-0414-y) (PMID:24570394)

Kavanaugh, A. et al. (2014) Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Annals of the Rheumatic Diseases, 73(6), pp. 1000-1006. (doi: 10.1136/annrheumdis-2013-204741) (PMID:24553909) (PMCID:PMC4033146)

McInnes, I.B. et al. (2014) Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Annals of the Rheumatic Diseases, 73(1), pp. 124-131. (doi: 10.1136/annrheumdis-2012-202442)

McInnes, I.B. et al. (2014) Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Annals of the Rheumatic Diseases, 73(2), pp. 349-356. (doi: 10.1136/annrheumdis-2012-202646) (PMID:23361084)

McInnes, I. B. , Cruwys, S., Bowers, K. and Braddock, M. (2014) Targeting the P2X7 receptor in rheumatoid arthritis: biological rationale for P2X7 antagonism. Clinical and Experimental Rheumatology, 32(6), pp. 878-882. (PMID:25288220)

Paul, L., Rafferty, D., Marshall-Mckenna, R. , Gill, J.M.R. , McInnes, I. , Porter, D. and Woodburn, J. (2014) Oxygen cost of walking, physical activity, and sedentary behaviours in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 43(1), pp. 28-34. (doi: 10.3109/03009742.2013.802009)

Ritchlin, C. et al. (2014) Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Annals of the Rheumatic Diseases, 73(6), pp. 990-999. (doi: 10.1136/annrheumdis-2013-204655) (PMID:24482301) (PMCID:PMC4033144)

Stalmach, A. , Johnsson, H., McInnes, I. B. , Husi, H., Klein, J., Dakna, M., Mullen, W. , Mischak, H. and Porter, D. (2014) Identification of urinary peptide biomarkers associated with rheumatoid arthritis. PLoS ONE, 9(8), e104625. (doi: 10.1371/journal.pone.0104625) (PMID:25144639) (PMCID:PMC4140712)

Turner, D. E., Hyslop, E., Barn, R., McInnes, I. B. , Steultjens, M. P.M. and Woodburn, J. (2014) Metatarsophalangeal joint pain in psoriatic arthritis: a cross-sectional study. Rheumatology, 53(4), pp. 737-740. (doi: 10.1093/rheumatology/ket435) (PMID:24369414)

2013

Baeten, D. et al. (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet, 382(9906), pp. 1705-1713. (doi: 10.1016/S0140-6736(13)61134-4) (PMID:24035250)

Lappin, D.F., Apatzidou, D., Quirke, A.M., Oliver-Bell, J., Butcher, J.P., Kinane, D.F., Riggio, M.P. , Venables, P., McInnes, I.B. and Culshaw, S. (2013) Influence of periodontal disease, porphyromonas gingivalisand cigarette smoking on systemic anti-citrullinated peptide antibody titres. Journal of Clinical Periodontology, 40(10), pp. 907-915. (doi: 10.1111/jcpe.12138) (PMID:23902301)

van den Berg, W.B. and McInnes, I.B. (2013) Th17 cells and IL-17 A—Focus on immunopathogenesis and immunotherapeutics. Seminars in Arthritis and Rheumatism, 43(2), pp. 158-170. (doi: 10.1016/j.semarthrit.2013.04.006) (PMID:24157091)

Burmester, G. R. et al. (2013) Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Annals of the Rheumatic Diseases, 72(9), pp. 1445-1452. (doi: 10.1136/annrheumdis-2012-202450) (PMID:23234647) (PMCID:PMC3756523)

Kavanaugh, A., McInnes, I. B. , Krueger, G. G., Gladman, D., Beutler, A., Gathany, T., Mack, M., Tandon, N., Han, C. and Mease, P. (2013) Patient reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of the GO-REVEAL trial. Arthritis Care and Research, NA-NA. (doi: 10.1002/acr.22044) (PMID:23666608) (PMCID:PMC4282022)

Robertson, J., Peters, M.J., McInnes, I.B. and Sattar, N. (2013) Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nature Reviews Rheumatology, 9(9), pp. 513-523. (doi: 10.1038/nrrheum.2013.91) (PMID:23774906)

McInnes, I.B. et al. (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet, 382(9894), pp. 780-789. (doi: 10.1016/S0140-6736(13)60594-2)

Schett, G., Elewaut, D., McInnes, I.B. , Dayer, J.-M. and Neurath, M.F. (2013) How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nature Medicine, 19(7), pp. 822-824. (doi: 10.1038/nm.3260)

Weir, R. A.P. et al. (2013) Response to letter regarding article, "Galectin-3 and cardiac function in survivors of acute myocardial infarction". Circulation: Heart Failure, 6(4), e58. (doi: 10.1161/CIRCHEARTFAILURE.113.000382)

Kapoor, S.R., Filer, A., Fitzpatrick, M.A., Fisher, B.A., Taylor, P.C., Buckley, C.D., McInnes, I.B. , Raza, K. and Young, S.P. (2013) Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. Arthritis and Rheumatism, 65(6), pp. 1448-1456. (doi: 10.1002/art.37921) (PMID:23460124) (PMCID:PMC3715109)

Weir, R. A.P. et al. (2013) Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circulation: Heart Failure, 6(3), pp. 492-498. (doi: 10.1161/CIRCHEARTFAILURE.112.000146) (PMID:23505301)

Zarpelon, A.C., Cunha, T.M., Alves-Filho, J.C., Pinto, L.G., Ferreira, S.H., McInnes, I.B. , Xu, D., Liew, F.Y., Cunha, F.Q. and Verri, W.A. (2013) IL-33/ST2 signalling contributes to carrageenin-induced innate inflammation and inflammatory pain: role of cytokines, endothelin-1 and prostaglandin E2. British Journal of Pharmacology, 169(1), pp. 90-101. (doi: 10.1111/bph.12110) (PMID:23347081) (PMCID:PMC3632241)

van der Heijde, D. et al. (2013) EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Annals of the Rheumatic Diseases, 72(4), pp. 479-481. (doi: 10.1136/annrheumdis-2012-202779)

Villeneuve, E. et al. (2013) Republished: a systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. Postgraduate Medical Journal, 89(1050), pp. 231-240. (doi: 10.1136/postgradmedj-2011-201063rep)

O'Shea, J.J., Laurence, A. and McInnes, I.B. (2013) Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nature Reviews Rheumatology, 9(3), pp. 173-182. (doi: 10.1038/nrrheum.2013.7) (PMID:23419429) (PMCID:PMC4169143)

Villeneuve, E. et al. (2013) A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. Annals of the Rheumatic Diseases, 72(1), pp. 13-22. (doi: 10.1136/annrheumdis-2011-201063) (PMID:23483130)

Wagner, C.L. et al. (2013) Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. Annals of the Rheumatic Diseases, 72(1), pp. 83-88. (doi: 10.1136/annrheumdis-2012-201697) (PMID:22975755) (PMCID:PMC3551220)

Asquith, D.L. et al. (2013) The liver X receptor pathway is highly upregulated in rheumatoid arthritis synovial macrophages and potentiates TLR-driven cytokine release. Annals of the Rheumatic Diseases, 72(12), pp. 2024-2031. (doi: 10.1136/annrheumdis-2012-202872) (PMID:23434566)

Coates, L.C. et al. (2013) The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology, 52(10), pp. 1754-1757. (doi: 10.1093/rheumatology/ket187) (PMID:23887065)

Crilly, A., Palmer, H.S., Nickdel, M.B., Dunning, L., Lockhart, J.C., Plevin, R., McInnes, I.B. and Ferrell, W.R. (2013) Immunomodulatory role of proteinase-activated receptor-2. Annals of the Rheumatic Diseases, 71(9), pp. 1559-1566. (doi: 10.1136/annrheumdis-2011-200869) (PMID:22563031)

Frleta, M., Rainey, A.-A., Gilchrist, D.S., Crawford, L., Baxter, D., Kurowska-Stolarska, M. and McInnes, I.B. (2013) Mir-27b as Biomarker and Regulator of IL-6R Pathway in Resistant Rheumatoid Arthritis Monocyte. In: 77th Annual Meeting of the American College of Rheumatology / 48th Annual Meeting of the Association of Rheumatology Health Professionals, San Diego, CA, 26-30 Oct 2013., S1035.

Jamnitski, A., Symmons, D., Peters, M.J.L., Sattar, N. , McInnes, I. and Nurmohamed, M.T. (2013) Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Annals of the Rheumatic Diseases, 72(2), pp. 211-216. (doi: 10.1136/annrheumdis-2011-201194)

Kavanaugh, A. et al. (2013) Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Annals of the Rheumatic Diseases, 72(11), pp. 1777-1785. (doi: 10.1136/annrheumdis-2012-202035)

McInnes, I.B. , Combe, B. and Burmester, G. (2013) Understanding the patient perspective: results of the rheumatoid arthritis: insights, strategies and expectations (RAISE) patient needs survey. Clinical and Experimental Rheumatology, 31(3), pp. 350-7. (PMID:23406685)

Millar, N. , Murrell, G.A.C. and McInnes, I. (2013) Alarmins in tendinopathy: unravelling new mechanisms in a common disease. Rheumatology, 52(5), pp. 769-779. (PMID:23362223)

Millar, N.L. , Gilchrist, D.S., Kurowska-Stolarska, M. , Murrell, G.A.C. and McInnes, I. B. (2013) The Interleukin 33/miR29 Axis Regulates Differential Collagen Production in Tendinopathy. In: EULAR 2013: Annual European Congress of Rheumatology, Madrid, Spain, 12-15 June 2013, p. 140.

Millar, N. L. , Gilchrist, D. S., Kurowska-Stolarska, M. , Murrell, G. A.C. and McInnes, I. (2013) The Interleukin 33/miR29 Axis Regulates Differential Collagen Production in Tendinopathy. In: 77th Annual Meeting of the American College of Rheumatology / 48th Annual Meeting of the Association of Rheumatology Health Professionals, San Diego, CA, 26-30 Oct 2013., S405.

Miller, A. M., Gilchrist, D. S., Nijjar, J., Araldi, E., Ramirez, C. M., Lavery, C. A., Fernández-Hernando, C., McInnes, I. B. and Kurowska-Stolarska, M. (2013) MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS ONE, 8(8), e72324. (doi: 10.1371/journal.pone.0072324) (PMID:23991091) (PMCID:PMC3749101)

Nijjar, J., Tindell, A., McInnes, I.B. and Siebert, S. (2013) Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatology, 52(9), pp. 1556-1562. (doi: 10.1093/rheumatology/ket225) (PMID:23861534)

Rainey, A.-A., Gilchrist, D. S., Tange, C. E., Frleta, M., Crawford, L., Baxter, D., McInnes, I. B. and Kurowska-Stolarska, M. (2013) Mir-125a: A novel regulator of IL-6 and TLR driven pathways in RA pathogenesis. In: 77th Annual Meeting of the American College of Rheumatology / 48th Annual Meeting of the Association of Rheumatology Health Professionals, San Diego, CA, 26-30 Oct 2013., S404.

Steven, R., Crilly, A., Lockhart, J. C., Ferrell, W. R. and McInnes, I. B. (2013) Proteinase-activated receptor-2 modulates human macrophage differentiation andeffector function. Innate Immunity, 19(6), pp. 663-672. (doi: 10.1177/1753425913479984) (PMID:23606513)

Tange, C. E., Alivernini, S., Gilchrist, D. S., Crawford, L., Rainey, A.-A., Baxter, D., McInnes, I. B. and Kurowska-Stolarska, M. (2013) Mir-34a in Rheumatoid Arthritis: characterisation of elevated synovial expression and association with treatment resistance. In: 77th Annual Meeting of the American College of Rheumatology / 48th Annual Meeting of the Association of Rheumatology Health Professionals, San Diego, CA, 26-30 Oct 2013., S403.

Woodburn, J., Hyslop, E., Barn, R., McInnes, I.B. and Turner, D. (2013) Achilles tendon biomechanics in psoriatic arthritis patients with ultrasound proven enthesitis. Scandinavian Journal of Rheumatology, 42(4), pp. 299-302. (doi: 10.3109/03009742.2012.747626) (PMID:23286761)

2012

Miller, A. M., Xu, D., Asquith, D. L., Denby, L., Li, Y., Sattar, N. , Baker, A. H., McInnes, I. B. and Liew, F. Y. (2012) IL-33 reduces the development of atherosclerosis (vol 205, pg 339, 2008). Journal of Experimental Medicine, 209(13), p. 2515. (doi: 10.1084/jem.2007186820913c)

MacRitchie, N. et al. (2012) Plasmacytoid dendritic cells play a key role in promoting atherosclerosis in apolipoprotein e-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(11), pp. 2569-2579. (doi: 10.1161/ATVBAHA.112.251314)

Patakas, A., Benson, R.A. , Withers, D.R., Conigliaro, P., McInnes, I.B. , Brewer, J.M. and Garside, P. (2012) Th17 effector cells support B bell responses outside of germinal centres. PLoS ONE, 7(11), e49715. (doi: 10.1371/journal.pone.0049715) (PMID:23166752) (PMCID:PMC3500323)

Miller, A. M. et al. (2012) Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS ONE, 7(10), e47830. (doi: 10.1371/journal.pone.0047830) (PMID:23112853) (PMCID:PMC3480428)

Haneklaus, M., Gerlic, M., Kurowska-Stolarska, M. , Rainey, A.-A., Pich, D., McInnes, I.B. , Hammerschmidt, W., O'Neill, L.A.J. and Masters, S.L. (2012) Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1 production. Journal of Immunology, 189(8), pp. 3795-3799. (doi: 10.4049/jimmunol.1200312) (PMID:22984081)

Keystone, E. C., Wang, M. M., Layton, M., Hollis, S. and McInnes, I.B. (2012) Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Annals of the Rheumatic Diseases, 71(10), pp. 1630-1635. (doi: 10.1136/annrheumdis-2011-143578) (PMID:22966146)

Utriainen, L., Firmin, D., Wright, P., Cerovic, V., Breban, M., McInnes, I. and Milling, S. (2012) Expression of HLA-B27 causes loss of migratory dendritic cells in a rat model of spondylarthritis. Arthritis and Rheumatism, 64(10), pp. 3199-3209. (doi: 10.1002/art.34561)

Weir, R. A.P., Miller, A. M., Petrie, C. J., Clements, S., Steedman, T., Dargie, H. J., Squire, I. B., Ng, L. L., McInnes, I. B. and McMurray, J. J.V. (2012) Interleukin-21 – a biomarker of importance in predicting myocardial function following acute infarction? Cytokine, 60(1), pp. 220-225. (doi: 10.1016/j.cyto.2012.06.002) (PMID:22748465)

Singh, M.D. et al. (2012) Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasis. American Journal of Pathology, 181(4), pp. 1158-1164. (doi: 10.1016/j.ajpath.2012.06.042) (PMID:22867710) (PMCID:PMC3532592)

Statache, G., Rainey, A.-A., Masters, S., Balanescu, A., McInnes, I. B. and Kurowska-Stolarska, M. (2012) Regulation of microrna 223 expression in a gouty arthritis. In: American College of Rheumatology & Association of Rheumatology Health Professionals, Annual Scientific Meeting, Washington DC, USA, 9-14 Nov 2012, S811. (doi: 10.1002/art.37735)

Tindell, A.G., Kelso, E.B., Ferrell, W.R., Lockhart, J.C., Walsh, D.A. , Dunning, L. and McInnes, I.B. (2012) Correlation of protease-activated receptor-2 expression and synovitis in rheumatoid and osteoarthritis. Rheumatology International, 32(10), pp. 3077-3086. (doi: 10.1007/s00296-011-2102-9) (PMID:21913036)

Komai-Koma, M. et al. (2012) Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naïve mice. Allergy, 67(9), pp. 1118-1126. (doi: 10.1111/j.1398-9995.2012.02859.x) (PMID:22702477) (PMCID:PMC3660789)

Elmesmari, A., Gilchrist, D., Fraser, A., Brewer, J. , McInnes, I. and Kurowska-Stolarska, M. (2012) The role of miR-155 in monocyte migration in Rheumatoid arthritis. In: European Congress of Immunology, Glasgow, UK, 5-8 Sept 2012, pp. 588-589. (doi: 10.1111/imm.12002)

Elmesmari, A., Pushparaj, P., Reilly, J., Kerr, S., Kurowska-Stolarska, M. and McInnes, I. (2012) The role of SPHKs and SIPRs in rheumatoid arthritis. In: European Congress of Immunology, Glasgow, UK, 5-8 Sept 2012, p. 260. (doi: 10.1111/imm.12002)

Statache, G., Rainey, A., Crawford, L., Masters, S., Balanescu, A., McInnes, I. and Kurowska-Stolarska, M. (2012) Regulation of microRNA 223 expression in a gouty arthritis. In: European Congress of Immunology, Glasgow, UK, 5-8 Sept 2012, p. 227. (doi: 10.1111/imm.12002)

Kavanaugh, A. et al. (2012) Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis and Rheumatism, 64(8), pp. 2504-2517. (doi: 10.1002/art.34436) (PMID:22378566)

Knox, S. et al. (2012) 25-hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid. Atherosclerosis, 223(2), pp. 437-441. (doi: 10.1016/j.atherosclerosis.2012.05.001) (PMID:22632919)

McInnes, I. , Lee, J.S., Thompson, L., Giles, J.T., Bathton, J.M., Salmon, J.E., Beaulieu, A.D., Codding, C.E., Delles, C. and Sattar, N. (2012) The effects of tocilizumab treatment on lipids and inflammatory/prothrombotic markers in patients (pts) with rheumatoid arthritis (RA): data from the randomized, controlled, measure study. European Heart Journal, 33(Sup 1), p. 281. (doi: 10.1093/eurheartj/ehs281)

Crilly, A. et al. (2012) PAR2 expression in peripheral blood monocytes of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 71(6), pp. 1049-1054. (doi: 10.1136/annrheumdis-2011-200703) (PMID:22294632)

Gibson, V.B. et al. (2012) A novel method to allow noninvasive, longitudinal imaging of the murine immune system in vivo. Blood, 119(11), pp. 2545-2551. (doi: 10.1182/blood-2011-09-378356) (PMID:22271449) (PMCID:PMC3398133)

Baxter, D., McInnes, I.B. and Kurowska-Stolarska, M. (2012) Novel regulatory mechanisms in inflammatory arthritis: a role for microRNA. Immunology and Cell Biology, 90(3), pp. 288-292. (doi: 10.1038/icb.2011.114) (PMID:22249200)

Elmesmari, A., Gilchrist, D. S., Fraser, A. D., Vaughan, D. , McQueenie, R., Graham, G. , Brewer, J. , McInnes, I. B. and Kurowska-Stolarska, M. (2012) Microrna-155 regulates chemokines and chemokine receptors in Rheumatoid Arthritis monocyte. In: American College of Rheumatology & Association of Rheumatology Health Professionals, Annual Scientific Meeting, Washington DC, USA, 9-14 Nov 2012, S384. (doi: 10.1002/art.37735)

Frleta, M., King, V., Reilly, J.H., Gilchrist, D.S., Tornehave, D., Lundsgaard, D., Miller, A.M. and McInnes, I.B. (2012) Expression of IL-21 receptor in synovial tissue and blood of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 71(Sup. 1), A83. (doi: 10.1136/annrheumdis-2011-201238.25)

Gossec, L. et al. (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases, 71(1), pp. 4-12. (doi: 10.1136/annrheumdis-2011-200350) (PMID:21953336)

Henningsson, L., Jirholt, P., Bogestal, Y.R., Eneljung, T., Adiels, M., Lindholm, C., McInnes, I. , Bulfone-Paus, S., Lerner, U.H. and Gjertsson, I. (2012) Interleukin 15 mediates joint destruction in Staphylococcus aureus arthritis. Journal of Infectious Diseases, 206(5), pp. 687-696. (doi: 10.1093/infdis/jis295)

Johnsson, H., McInnes, I.B. and Sattar, N. (2012) Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence. Annals of the Rheumatic Diseases, 71(4), pp. 480-483. (doi: 10.1136/annrheumdis-2011-200567) (PMID:22294632)

Kerekes, G., Soltész, P., Nurmohamed, M.T., Gonzalez-Gay, M.A., Turiel, M., Végh, E., Shoenfeld, Y., McInnes, I. and Szekanecz, Z. (2012) Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nature Reviews Rheumatology, 8(4), pp. 224-234. (doi: 10.1038/nrrheum.2012.16)

Kurowska-Stolarska, M. , Hasoo, M., Gilchrist, D. G., Ruzicska, E., Asquith, D., Welsh, D., Crawford, L., Hirani, N., McInnes, I. B. and McSharry, C. (2012) Microrna-155 protects against pulmonary fibrosis by targeting the transcription regulator LXR alpha. In: American College of Rheumatology & Association of Rheumatology Health Professionals, Annual Scientific Meeting, Washington DC, USA, 9-14 Nov 2012, S386. (doi: 10.1002/art.37735)

Lories, R.J. and McInnes, I.B. (2012) Primed for inflammation: enthesis-resident T cells. Nature Medicine, 18(7), pp. 1018-1019. (doi: 10.1038/nm.2854) (PMID:22772553)

McQueenie, R., Stevenson, R., Benson, R. , MacRitchie, N., McInnes, I. , Maffia, P. , Faulds, K., Graham, D., Brewer, J. and Garside, P. (2012) Detection of inflammation in vivo by surface-enhanced raman scattering provides higher sensitivity than conventional fluorescence imaging. Analytical Chemistry, 84(14), pp. 5968-5975. (doi: 10.1021/ac3006445)

Millar, N.L. , Reilly, J.H., Kerr, S.C., Campbell, A.L., Little, K.J., Leach, W.J., Rooney, B.P., Murrell, G.A.C. and McInnes, I.B. (2012) Hypoxia: a critical regulator of early human tendinopathy. Annals of the Rheumatic Diseases, 71(2), pp. 302-310. (doi: 10.1136/ard.2011.154229) (PMID:21972243)

Patakas, A., Benson, R.A. , Withers, D.R., Conigliaro, P., McInnes, I.B. , Brewer, J.M. and Garside, P. (2012) Th17 effector cells support B cell responses outside of germinal centres. PLoS ONE, 7(11), e49715. (doi: 10.1371/journal.pone.0049715) (PMID:23161902) (PMCID:PMC3812864)

Steinman, L., Merrill, J.T., McInnes, I.B. and Peakman, M. (2012) Optimization of current and future therapy for autoimmune diseases. Nature Medicine, 18(1), pp. 59-65. (doi: 10.1038/nm.2625) (PMID:22227674)

Wenink, M.H., Santegoets, K.C.M., Platt, A.M., van den Berg, W.B., van Riel, P.L.C.M., Garside, P. , Radstake, T.R.D.J. and McInnes, I.B. (2012) Abatacept modulates proinflammatory macrophage responses upon cytokine-activated T cell and Toll-like receptor ligand stimulation. Annals of the Rheumatic Diseases, 71(1), pp. 80-83. (doi: 10.1136/annrheumdis-2011-200348) (PMID:21908454)

Xuzhu, G., Komai-Koma, M., Leung, B.P., Howe, H.S., McSharry, C., McInnes, I.B. and Xu, D. (2012) Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Annals of the Rheumatic Diseases, 71(1), pp. 129-135. (doi: 10.1136/ard.2011.149831) (PMID:21953348)

2011

McInnes, I.B. and Schett, G. (2011) The pathogenesis of rheumatoid arthritis. New England Journal of Medicine, 365(23), pp. 2205-2219. (doi: 10.1056/NEJMra1004965) (PMID:22150039)

Benson, R.A. , Patakas, A., McQueenie, R., Ross, K., McInnes, I.B. , Brewer, J.M. and Garside, P. (2011) Arthritis in space and time – to boldly go! FEBS Letters, 585(23), pp. 2640-3648. (doi: 10.1016/j.febslet.2011.04.069) (PMID:21570969)

MacLellan, L. M., Montgomery, J., Sugiyama, F., Kitson, S. M., Thümmler, K. , Silverman, G. J., Beers, S. A., Nibbs, R. J.B. , McInnes, I. B. and Goodyear, C. S. (2011) Co-opting endogenous immunoglobulin for the regulation of inflammation and osteoclastogenesis in humans and mice. Arthritis and Rheumatism, 63(12), pp. 3897-3907. (doi: 10.1002/art.30629) (PMID:22127707) (PMCID:PMC3598489)

Wenink, M.H., Santegoets, K.C.M., Butcher, J., van Bon, L., Lamers-Karnebeek, F.G.M., van den Berg, W.B., van Riel, P.L.C.M., McInnes, I.B. and Radstake, T.R.D.J. (2011) Impaired dendritic cell proinflammatory cytokine production in psoriatic arthritis. Arthritis and Rheumatism, 63(11), pp. 3313-3322. (doi: 10.1002/art.30577) (PMID:21811995)

Welsh, P. et al. (2011) Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(10), pp. 2338-2344. (doi: 10.1161/ATVBAHA.111.231795) (PMID:21757655)

Hueber, A. J., Alves-Filho, J. C., Asquith, D. L., Michels, C., Millar, N. L. , Reilly, J. H., Graham, G. J. , Liew, F. Y., Miller, A. M. and McInnes, I. B. (2011) IL-33 induces skin inflammation with mast cell and neutrophil activation. European Journal of Immunology, 41(8), pp. 2229-2237. (doi: 10.1002/eji.201041360) (PMID:21674479)

Conigliaro, P., Benson, R. A. , Patakas, A., Kelly, S. M., Valesini, G., Holmdahl, R., Brewer, J. M. , McInnes, I. B. and Garside, P. (2011) Characterization of the anticollagen antibody response in a new model of chronic polyarthritis. Arthritis and Rheumatism, 63(8), pp. 2299-2308. (doi: 10.1002/art.30413) (PMID:21506101)

Kurowska-Stolarska, M. et al. (2011) MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proceedings of the National Academy of Sciences of the United States of America, 108(27), pp. 11193-11198. (doi: 10.1073/pnas.1019536108) (PMID:21690378)

Patakas, A., Platt, A. M., Butcher, J. P., Maffia, P. , McInnes, I. B. , Brewer, J. M. , Garside, P. and Benson, R. A. (2011) Putative existence of reciprocal dialogue between Tfh and B cells and its impact on infectious and autoimmune disease. Immunology Letters, 138(1), pp. 38-46. (doi: 10.1016/j.imlet.2011.03.002) (PMID:21419798)

Crilly, A., Robertson, S.E., Reilly, J.H., Gracie, J.A., Lai, W.-Q., Leung, B.P., Life, P.F. and McInnes, I.B. (2011) Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane. Annals of the Rheumatic Diseases, 70(6), pp. 1130-1137. (doi: 10.1136/ard.2010.134825) (PMID:21342916)

Zaiss, M. M. et al. (2011) IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-α–mediated bone loss. Journal of Immunology, 186(11), pp. 6097-6105. (doi: 10.4049/jimmunol.1003487) (PMID:21515798)

Welsh, P. et al. (2011) Vitamin D deficiency is common in patients with RA and linked to disease activity, but circulating levels are unaffected by TNF blockade: results from a prospective cohort study. Annals of the Rheumatic Diseases, 70(6), pp. 1165-1167. (doi: 10.1136/ard.2010.137265) (PMID:21047908)

Hansell, C. A. H., Schiering, C., Kinstrie, R., Ford, L., Bordon, Y., McInnes, I. B. , Goodyear, C. S. and Nibbs, R. J.B. (2011) Universal expression and dual function of the atypical chemokine receptor D6 on innate-like B cells in mice. Blood, 117(20), pp. 5413-5424. (doi: 10.1182/blood-2010-11-317115) (PMID:21450903) (PMCID:PMC3188399)

Krishnadas, R. , Mallon, V., McInnes, I. and Cavanagh, J. (2011) Correlates of depression and quality of life in patients with inflammatory arthritides. European Psychiatry, 26, p. 383. (doi: 10.1016/S0924-9338(11)72091-0)

Norman, J.E., Yuan, M., Anderson, L., Howie, F., Harold, G., Young, A., Jordan, F., McInnes, I. and Harnett, M.M. (2011) Effect of prolonged in vivo administration of progesterone in pregnancy on myometrial gene expression, peripheral blood leukocyte activation, and circulating steroid hormone levels. Reproductive Sciences, 18(5), pp. 435-446. (doi: 10.1177/1933719110395404)

Priori, R., Barone, F., Alessandri, C., Colafrancesco, S., McInnes, I. B. , Pitzalis, C., Valesini, G. and Bombardieri, M. (2011) Markedly increased IL-18 liver expression in adult-onset Still's disease-related hepatitis. Rheumatology, 50(4), pp. 776-780. (doi: 10.1093/rheumatology/keq397) (PMID:21149398)

Culshaw, S. , McInnes, I. B. and Liew, F. Y. (2011) What can the periodontal community learn from the pathophysiology of rheumatoid arthritis? Journal of Clinical Periodontology, 38(S11), pp. 106-113. (doi: 10.1111/j.1600-051X.2010.01669.x) (PMID:21323707)

Codullo, V. et al. (2011) An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Annals of the Rheumatic Diseases, 70(6), pp. 1115-1121. (doi: 10.1136/ard.2010.137349) (PMID:21285114)

Miller, A. and McInnes, I. (2011) Cytokines as therapeutic targets to reduce cardiovascular risk in chronic inflammation. Current Pharmaceutical Design, 17(1), pp. 1-8. (doi: 10.2174/138161211795049796) (PMID:21222645)

Alivernini, S. et al. (2011) The role of microRNA-34 and microRNA-22 in dendritic cells and monocyte activation in rheumatoid arthritis. In: American College of Rheumatology & Association of Rheumatology Health Professionals, Annual Scientific Meeting, Chicago, IL USA, 4-9 Nov 2011, S654.

Asquith, D.L., Miller, A.M., Reilly, J.H., Kerr, S., Welsh, P. , Sattar, N. and McInnes, I.B. (2011) Simultaneous activation of the liver X receptors (LXR and LXR) drives murine collagen-induced arthritis disease pathology. Annals of the Rheumatic Diseases, 70(12), pp. 2225-2228. (doi: 10.1136/ard.2011.152652) (PMID:21859686.)

Bombardieri, M., Kam, N.-W., Brentano, F., Choi, K., Filer, A., Kyburz, D., McInnes, I.B. , Gay, S., Buckley, C. and Pitzalis, C. (2011) A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. Annals of the Rheumatic Diseases, 70(10), pp. 1857-1865. (doi: 10.1136/ard.2011.150219) (PMID:21798884)

Codullo, V. and McInnes, I. B. (2011) Synovial tissue response to treatment in psoriatic arthritis. Open Rheumatology Journal, 5(1), pp. 133-137. (doi: 10.2174/1874312901105010133) (PMID:22279513) (PMCID:PMC3263446)

Laing, S., Hernandez-Santana, A., Sassmannshausen, J., Asquith, D.L., McInnes, I.B. , Faulds, K. and Graham, D. (2011) Quantitative detection of human tumor necrosis factor α by a resonance raman enzyme-linked immunosorbent assa. Analytical Chemistry, 83(1), pp. 297-302. (doi: 10.1021/ac1024039) (PMID:21121688)

Pitman, N., Asquith, D.L., Murphy, G., Liew, F.Y. and McInnes, I.B. (2011) Collagen-induced arthritis is not impaired in mast cell-deficient mice. Annals of the Rheumatic Diseases, 70(6), pp. 1170-1171. (doi: 10.1136/ard.2010.134528) (PMID:21131642)

Stevenson, R., Hueber, A. J., Hutton, A., McInnes, I. B. and Graham, D. (2011) Nanoparticles and Inflammation. Scientific World Journal, 11, pp. 1300-1312. (doi: 10.1100/tsw.2011.106) (PMID:21666995)

van de Sande, M. G. H. et al. (2011) Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Annals of the Rheumatic Diseases, 70(3), pp. 423-427. (doi: 10.1136/ard.2010.139550) (PMID:21109518)

Wenink, M. H., Santegoets, K. C.M., van Bon, L., Butcher, J., van den Berg, W. B., van Riel, P. L.C.M., McInnes, I. B. and Radstake, T. R.D.J. (2011) Macrophage dysfunction in psoriatic arthritis. Journal of Translational Medicine, 9(Sup 2), P59. (doi: 10.1186/1479-5876-9-S2-P59) (PMCID:PMC3242289)

Zwerina, K. et al. (2011) Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance. European Journal of Immunology, 42(2), pp. 413-423. (doi: 10.1002/eji.201141871)

2010

Woodburn, J., Hennessy, K., Steultjens, M. P. M., McInnes, I. B. and Turner, D. E. (2010) Looking through the 'window of opportunity': is there a new paradigm of podiatry care on the horizon in early rheumatoid arthritis? Journal of Foot and Ankle Research, 3(1), 8. (doi: 10.1186/1757-1146-3-8) (PMID:0478038) (PMCID:PMC2883976)

Miller, A. M., Asquith, D. L., Hueber, A. J., Anderson, L. A., Holmes, W. M. , McKenzie, A. N., Xu, D., Sattar, N. , McInnes, I. B. and Liew, F. Y. (2010) Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circulation Research, 107(5), pp. 650-658. (doi: 10.1161/CIRCRESAHA.110.218867) (PMID:20634488) (PMCID:PMC4254700)

Verri, W. A. et al. (2010) IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Annals of the Rheumatic Diseases, 69(9), pp. 1697-1703. (doi: 10.1136/ard.2009.122655) (PMID:20472598)

Peters, M. J. L., Watt, P., Cherry, L., Welsh, P. , Henninger, E., Dijkmans, B. A. C., McInnes, I. B. , Nurmohamed, M. T. and Sattar, N. (2010) Lack of effect of TNFα blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies. Annals of the Rheumatic Diseases, 69(9), pp. 1687-1690. (doi: 10.1136/ard.2009.114207) (PMID:19640853)

Emery, P., Buch, M.H., Östör, A., Kirkham, B., Taylor, P., Estrach, C., Jenkinson, T., McInnes, I. and Porter, D. (2010) Time for treatment targets in rheumatoid arthritis. British Medical Journal, 341(c4170), p. 267. (doi: 10.1136/bmj.c4170)

Platt, A. M., Gibson, V. B., Patakas, A., Benson, R. A. , Nadler, S. G., Brewer, J. M. , McInnes, I. and Garside, P. (2010) Abatacept limits breach of self-tolerance in a Murine model of arthritis via effects on the generation of T follicular helper cells. Journal of Immunology, 185(3), pp. 1558-1567. (doi: 10.4049/jimmunol.1001311) (PMID:20601593)

McInnes, I. B. and O’Dell, J. R. (2010) Novel therapeutics – exciting gifts but how best to use them? Best Practice and Research: Clinical Rheumatology, 24(4), pp. 441-442. (doi: 10.1016/j.berh.2010.03.002) (PMID:20732642)

Peters, M. J. L., Welsh, P. , McInnes, I. B. , Wolbink, G., Dijkmans, B. A. C., Sattar, N. and Nurmohamed, M. T. (2010) Tumour necrosis factor α blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Annals of the Rheumatic Diseases, 69(7), pp. 1281-1285. (doi: 10.1136/ard.2009.119412) (PMID:19934107)

Benson, R.A. , Patakas, A., Conigliaro, P., Rush, C. M., Garside, P. , McInnes, I. B. and Brewer, J. M. (2010) Identifying the Cells Breaching Self-Tolerance in Autoimmunity. Journal of Immunology, 184(11), pp. 6378-6385. (doi: 10.4049/jimmunol.0903951) (PMID:20421640)

Hueber, A. J., Asquith, D. L., Miller, A. M., Reilly, J., Kerr, S., Leipe, J., Melendez Romero, A. J. and McInnes, I. B. (2010) Cutting Edge: Mast Cells Express IL-17A in Rheumatoid Arthritis Synovium. Journal of Immunology, 184(7), pp. 3336-3340. (doi: 10.4049/jimmunol.0903566) (PMID:20200272)

Xu, D. et al. (2010) IL-33 exacerbates autoantibody-induced arthritis. Journal of Immunology, 184(5), pp. 2620-2626. (doi: 10.4049/jimmunol.0902685) (PMID:20139274)

Asquith, D. L., Miller, A. M., Hueber, A. J., Liew, F. Y., Sattar, N. and McInnes, I. B. (2010) Apolipoprotein E-deficient mice are resistant to the development of collagen-induced arthritis. Arthritis and Rheumatism, 62(2), pp. 472-477. (doi: 10.1002/art.27205) (PMID:20112375)

Liew, F. Y., Pitman, N. I. and McInnes, I. B. (2010) Disease-associated functions of IL-33: the new kid in the IL-1 family. Nature Reviews Immunology, 10(2), pp. 103-110. (doi: 10.1038/nri2692) (PMID:20081870)

Weir, R.A.P., Miller, A.M., Murphy, G., Clements, S., Steedman, T., Connell, J., McInnes, I. , Dargie, H. and McMurray, J.J. (2010) Serum soluble ST2 a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. Journal of the American College of Cardiology, 55(3), pp. 243-250. (doi: 10.1016/j.jacc.2009.08.047) (PMID:20117403)

Murphy, G.E.J., Xu, D., Liew, F.Y. and McInnes, I.B. (2010) Role of interleukin 33 in human immunopathology. Annals of the Rheumatic Diseases, 69(Suppl), pp. 43-47. (doi: 10.1136/ard.2009.120113) (PMID:19995743)

Cavanagh, J. , Paterson, C., McLean, J., Pimlott, S. , McDonald, M., Patterson, J., Wyper, D. and McInnes, I. (2010) Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study. Annals of the Rheumatic Diseases, 69(6), 1251-U367. (doi: 10.1136/ard.2009.107912)

Ferrell, W.R., Kelso, E.B., Lockhart, J.C., Plevin, R. and McInnes, I.B. (2010) Protease-activated receptor 2: a novel pathogenic pathway in a murine model of osteoarthritis. Annals of the Rheumatic Diseases, 69(11), pp. 2051-2054. (doi: 10.1136/ard.2010.130336) (PMID:20584806)

Fraser, A.R., Perry, M.E., Crilly, A., Reilly, J.H., Hueber, A.J. and McInnes, I.B. (2010) Lipoma arborescens co-existing with psoriatic arthritis releases tumour necrosis factor alpha and matrix metalloproteinase. Annals of the Rheumatic Diseases, 69(4), pp. 776-777. (doi: 10.1136/ard.2008.106047) (PMID:20237127)

Grassia, G., Dever, G., Gordon, P., McInnes, I. , Spanbroek, R., Habenicht, A.J.R., Brewer, J. , Garside, P. and Maffia, P. (2010) Real time imaging of lymphocytes in APOE-/- mouse aortic tertiary lymphoid organs. In: Spring Meeting of the British-Society-for-Cardiovascular-Research 2010, Manchester, UK, 07-08 June 2010, e12. (doi: 10.1136/hrt.2010.205781.11)

Hueber, A.J., Asquith, D.L., McInnes, I.B. and Miller, A.M. (2010) Embracing novel cytokines in RA – complexity grows as does opportunity! Best Practice and Research: Clinical Rheumatology, 24(4), pp. 479-487. (doi: 10.1016/j.berh.2010.01.004) (PMID:20732646)

Hyslop, E., McInnes, I. B. , Woodburn, J. and Turner, D. E. (2010) Foot problems in psoriatic arthritis: high burden and low care provision. Annals of the Rheumatic Diseases, 69(5), p. 928. (doi: 10.1136/ard.2009.111971) (PMID:20413569)

Hyslop, E., Woodburn, J., McInnes, I.B. , Semple, R., Newcombe, L., Hendry, G., Rafferty, D., De Mits, S. and Turner, D.E. (2010) A reliability study of biomechanical foot function in psoriatic arthritis based on a novel multi-segmented foot model. Gait and Posture, 32(4), pp. 619-626. (doi: 10.1016/j.gaitpost.2010.09.004) (PMID:20889342)

Kurowska-Stolarska, M. , Hueber, A., Stolarski, B. and McInnes, I. B. (2010) Interleukin-33: a novel mediator with a role in distinct disease pathologies. Journal of Internal Medicine, 269(1), pp. 29-35. (doi: 10.1111/j.1365-2796.2010.02316.x) (PMID:21158975)

Kurowska-Stolarska, M. , Ballantine, L., Stolarski, B., Hunter, J., Hueber, A., Gracie, J.A., Liew, F. Y. and McInnes, I. B. (2010) miR-155 and miR-34a regulate proinflammatory cytokine production by human monocytes. In: European Workshop for Rheumatology Research, Bamberg, Germany, 4-7 Mar 2010, A30-A30. (doi: 10.1136/ard.2010.129619g)

McInnes, I. B. and O'Dell, J. R. (2010) State-of-the-art: rheumatoid arthritis. Annals of the Rheumatic Diseases, 69(11), pp. 1898-1906. (doi: 10.1136/ard.2010.134684) (PMID:20959326)

Millar, N.L. , Hueber, A.J., Reilly, J.H., Xu, Y., Fazzi, U.G., Murrell, G.A.C. and McInnes, I.B. (2010) Inflammation is present in early human tendinopathy. American Journal of Sports Medicine, 38(10), pp. 2085-2091. (doi: 10.1177/0363546510372613) (PMID:20595553)

Peters, M. J. L. et al. (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the Rheumatic Diseases, 69(2), pp. 325-331. (doi: 10.1136/ard.2009.113696) (PMID:19773290)

2009

Kurowska-Stolarska, M. et al. (2009) IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway Inflammation. Journal of Immunology, 183(10), pp. 6469-6477. (doi: 10.4049/jimmunol.0901575) (PMID:19841166)

Asquith, D., Miller, A., Hueber, A., McKinnon, H., Sattar, N., Graham, G. and McInnes, I. (2009) Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis. Arthritis and Rheumatism, 60(9), pp. 2655-2665. (doi: 10.1002/art.24717) (PMID:19714646)

Lai, W.-Q., Irwan, A. W., Goh, H. H., Melendez, A. J., McInnes, I. B. and Leung, B. P. (2009) Distinct roles of sphingosine kinase 1 and 2 in murine collagen-induced arthritis. Journal of Immunology, 183(3), pp. 2097-2103. (doi: 10.4049/jimmunol.0804376) (PMID:19596980)

Asquith, D. L., Miller, A. M., McInnes, I. B. and Liew, F. Y. (2009) Animal models of rheumatoid arthritis. European Journal of Immunology, 39(8), pp. 2040-2044. (doi: 10.1002/eji.200939578) (PMID:19672892)

McKellar, G. E., McCarey, D. W., Sattar, N. and McInnes, I. B. (2009) Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nature Reviews Cardiology, 6(6), pp. 410-417. (doi: 10.1038/nrcardio.2009.57) (PMID:19421244)

Gabay, C. and McInnes, I. B. (2009) The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases. Arthritis Research and Therapy, 11(3), (doi: 10.1186/ar2680) (PMID:19519923)